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Abstract 
Histopathological analysis of tumor is currently the main tool used to guide cancer 
management. Gene expression profiling may provide additional valuable information for 
both classification and prognostication of individual tumors. A number of gene expression 
profiling assays have been developed recently to inform therapy decisions in women with 
early stage breast cancer and help identify the primary tumor site in patients with metastatic 
cancer of unknown primary. The impact of these assays on health and economic outcomes, if 
introduced into general practice, has not been determined. I aimed to conduct an economic 
evaluation of regulatory-approved gene expression profiling assays for breast cancer and 
cancer of unknown primary for the purpose of determining whether these technologies 
represent value for money from the perspective of the Canadian health care system. I 
developed decision-analytic models to project the lifetime clinical and economic 
consequences of early stage breast cancer and metastatic cancer of unknown primary. I used 
Manitoba Cancer Registry and Manitoba administrative health databases to model current 
“real-world” Canadian clinical practices. I applied available data about gene expression 
profiling assays from secondary sources on these models to predict the impact of these assays 
on current clinical and economic outcomes. In the base case, gene expression profiling assays 
in early stage breast cancer and cancer of unknown primary resulted in incremental cost 
effectiveness ratios of less than $100,000 per quality-adjusted life-year gained. These results 
were most sensitive to the uncertainty associated with the accuracy of the assay, patient-
physician response to gene expression profiling information and patient survival. The 
potential application of these gene expression profiling assays in clinical oncology appears to 
be cost-effective in the Canadian healthcare system. Field evaluation of these assays to 
establish their impact on cancer management and patient survival may have a large societal 
impact and should be initiated in Canada to ensure their clinical utility and cost-effectiveness. 
The use of Canadian provincial administrative population data in decision modeling is useful 
to quantify uncertainty about gene expression profiling assays and guide the use of novel 
funding models such as conditional funding alongside a field evaluation.  
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Chapter 1  
1 Introduction 
1.1 Gene expression profiling 
Current goals in cancer research include the discovery of new cellular targets to exploit 
for new targeted treatments, new biomarkers for early cancer detection, and providing a 
better classification of cancers for prognostication and treatment decision [1]. Toward 
this end, significant research efforts have been made to understand the molecular basis of 
carcinogenesis and the biologic behavior of human cancers [1]. Due to the complexity of 
the molecular alterations in tumor cells, progress has been slow. Carcinogenesis is a 
multistep process in which cells accumulate altered expression of numerous genes as they 
progress to a more malignant phenotype [2]. Confounding this complexity, many of the 
so-called oncogenes and tumor suppressor genes are signaling molecules, which control 
the expression of a subset of downstream genes [2]. 
Cells respond to environmental signals by modulating the expression of genes contained 
within the nucleus. When genes are activated, they are transcribed to generate messenger 
RNA (mRNA), which is transported from the nucleus to the cytoplasm and translated into 
protein by the ribosomes. 
Approximately 3 to 5 percent of genes are active in a particular cell, even though all cells 
have the same information contained in their DNA. Most of the genome is selectively 
repressed, a property that is managed by the regulation of gene expression, mostly in 
transcription (i.e. the production of messenger RNA from the DNA). Changes in gene 
expression in response to a cellular perturbation take place that result in the expression of 
hundreds of gene products and the suppression of others. This molecular heterogeneity is 
thought to explain, at least in part, the variability in outcome and response to therapy that 
characterizes tumors of different histology [1-2]. 
Even tumors of a specific histological type can be quite heterogeneous. In general, 
histopathological analysis of tumor tissue is the main tool that guides clinical 
management decisions and prognostic estimates [1-2]. However, tumor behavior cannot 
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be adequately understood through the analysis of one or a small numbers of genes, 
particularly for the common solid tumors. 
The analysis of multiple expressed genes or proteins provides more valuable information 
for both classification and prognostication of individual tumors [1-2]. The development 
of microarray methodology, which permits the expression of thousands of genes to be 
tested simultaneously, represents a powerful technique to read the "molecular signature" 
of an individual patient's tumor [3]. This process is called gene expression profiling. 
Analyzing gene expression patterns among individual patients with the similar disease 
may disclose molecular differences. Such classification may allow better treatment 
selection and prognostication [2, 4]. 
While these discoveries increase our understanding of molecular pathogenesis, they can 
also suggest novel therapeutic targets, provide information about drug resistance 
pathways, and refine diagnostic and prognostic classifications [4]. For instance, a major 
problem in clinical oncology is the heterogeneous response of histologically similar 
tumors to treatments such as cytotoxic chemotherapy [5]. With the exception of estrogen 
or progesterone receptor, and human epidermal growth factor receptor 2 (HER-2) 
expression in breast cancer (for hormonal therapy and trastuzumab, respectively) [6], 
epidermal growth factor receptor (EGFR) kinase domain mutations and genomic 
amplification in lung cancer (in EGFR targeted inhibitors gefitinib or erlotinib) [7], and 
K-ras mutations in colon cancer (lack of response to EGFR-targeted antagonists) [8], 
there are no other single molecules that are clinically valuable predictors of response 
validated for any form of anticancer therapy. 
Growing data suggest that prediction of response to chemotherapy or biologically 
targeted agents may be possible by analyzing gene expression profiles [9]. With rapid 
advances in the DNA microarray technologies and more sophisticated studies, microarray 
analysis has begun to make ways into clinical trials and practices in oncology [10-12]. 
Particularly, two major areas of investigation are the use of gene expression profiling 
assays to guide cancer therapy and cancer diagnosis.  
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1.1.1 Gene expression profiling to guide cancer therapy 
 A major area of investigation is the use of such molecular profiling to predict response to 
therapy [13-17]. Gene expression profiling analysis by DNA microarray is now available 
in patients with breast cancer to quantify the likelihood of a breast cancer recurrence in 
women with newly diagnosed, hormone receptor-positive early stage breast cancer [11, 
18-20]. Furthermore, there is growing evidence that gene expression profiling analyses 
can help predict which patients are most likely to benefit from chemotherapy [11, 18-20]. 
To date, several gene expression-based tests have demonstrated the potential value of this 
approach. The 21-gene recurrence score (RS) assay (Oncotype DX, Genomic Health Inc., 
Redwood City, CA) [11, 18] and MammaPrint (Agendia, Irvine, CA and Amsterdam, 
The Netherlands) [21-22] are commercially available gene expression profiling assays 
that are used to inform treatment decisions based on tumour biology. However, the RS-
assay is becoming widely accepted as having clinical validity and utility for this purpose 
[23]. 
The RS-assay is a RT-qPCR based signature that measures the expression of 21 genes (16 
cancer related and 5 reference genes). RNA is obtained from formalin-fixed paraffin-
embedded (FFPE) tissue samples. The RS-assay is recommended for patients with 
hormone receptor positive and human epidermal growth factor receptor 2 (HER-2) not 
over expressed axillary lymph node negative early stage breast cancer. The test requires 
assessment of estrogen receptor and HER-2 status by an alternative method [18]. The RS-
assay became the most widely used clinical gene expression assay in the United States. 
The genes in the assay were selected from 250 candidates that were tested for association 
with survival in a cohort of 447 tumor samples, from the tamoxifen treated and node 
negative cases of the National Surgical Adjuvant and Breast Project (NSABP) B-20 
clinical trial [24]. The RS-assay was validated in a large cohort of estrogen receptor 
positive node negative breast cancer patients treated with tamoxifen, enrolled in the 
NSABP B-14 study [18]. In this study, the rates of distant recurrence at 10 years were 
6.8%, 14.3%, and 30.5% for the low-risk, intermediate, and high-risk groups, 
respectively [18]. The RS is a continuous variable, ranging from 0 to 100, and constitutes 
a measure of the risk of relapse within 10 years. The score is an independent prognostic 
factor for patients with hormone receptor positive breast cancer treated with adjuvant 
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tamoxifen. Patients can be classified into three categories on the basis of RS. Low risk 
(RS<18), intermediate (RS 18-31), and high (RS>31), which equate with 10 year relapse 
rates of 7%, 14%, and 30%, respectively. Women in the low risk group do not seem to 
benefit from adjuvant chemotherapy as shown in the NSABP-B20 analysis that randomly 
assigned patients to receive cyclophosphamide, methotrexate, 5-fluorouracil (CMF)  
chemotherapy with concurrent tamoxifen or tamoxifen alone [11]. Only a small subset of 
tissues was available for analysis (651 samples from 2363 randomized patients). The 
analysis showed that their distant metastasis free survival is higher than 90% regardless 
whether or not they received CMF chemotherapy. In contrast, women in the high-risk 
group derived benefit from adjuvant CMF chemotherapy [11]. The question remains 
unanswered for women who fall into the intermediate-risk group. The current ongoing 
Trial Assigning IndividuaLized Options for Treatment (TAILORx) [25] and Southwest 
Oncology Group (SWOG) S-1007 [26]) seeks to answer this question by randomly 
assigning patients with intermediate RS to adjuvant chemotherapy followed by anti-
estrogen treatment or anti estrogen treatment alone.  
MammaPrint (Agendia, Irvine, CA and Amsterdam, The Netherlands) is a microarray-
based gene-expression profiling assay of RNA [21-22]. The test is comprised of 70 genes 
identified from an initially unselected set of all >25,000 genes within the human genome 
which were obtained from fresh frozen samples of tumor tissue [21]. New studies have 
demonstrated that the test could be done by RT-qPCR, both in fresh frozen and formalin-
fixed paraffin embedded tissue, with equivalent performance [27]. The genes are 
associated with all hallmarks of cancer including proliferation, invasion, and 
angiogenesis. The genes were obtained from tissue of 78 patients with lymph node 
negative breast cancers, most of which were hormone receptor positive tumors and did 
not receive adjuvant systemic therapy [21]. This signature has been validated on 
numerous cohorts of node negative patients, and has demonstrated to provide 
independent prognostic information beyond standard clinicopathological variables such 
as age, histology, tumour grade and pathological stage [21, 28-29]. The test can be used 
in estrogen negative breast tumors. 
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Mammaprint is the first and so far only Food and Drug Administration (FDA)-approved 
gene-expression assay to be used as prognostic test for women with node-negative breast 
cancers [30]. The test yields two prognostic groups: low-risk and high-risk. This 
signature is predictive of both distant disease-free survival and overall survival when 
adjusted for lymph node status. Patients in the low-risk group have a distant metastasis 
free survival of over 90% without the addition of systemic chemotherapy [21].  
Overall published evidence supports MammaPrint as a better predictor of the risk of 
distant recurrence than traditionally used tumour characteristics or algorithms, but its 
performance in therapeutically homogenous populations is not yet known with precision, 
and it is unclear for how many women the lowest predicted risks are low enough to forgo 
chemotherapy [23]. No evidence is available to permit conclusions regarding the clinical 
utility of MammaPrint to select women who will benefit from chemotherapy [23].  
The key components of the RS-assay used for clinical care are the RS and corresponding 
RS category [23]. These data are based on the clinical trials from which the RS-assay 
method was derived and validated. Although the MammaPrint and other assays under 
development [30] do provide risk categories, the available evidence does not show that 
the results of these assays have equivalent clinical utility to the RS-assay [23]. In 
particular, the RS can be interpreted in the context of the NSABP B14 and B20 clinical 
trials [11, 18] data to estimate the probability of recurrence without treatment and of 
chemotherapy benefit, respectively.  The equivalent data cannot be extracted from other 
assays. In addition, direct prospective comparisons between the RS-assay and alternatives 
are lacking. 
Gene expression profiling assays are also being investigated as a tool to predict the 
likelihood of disease recurrence and guide adjuvant treatment in individuals with colon 
cancer [31]. Currently, five tests have been launched and shown to have prognostic value 
in independent patient series, although the designs and sample numbers of the validation 
analyses have varied [32-33]. The 12-gene assay (Oncotype Dx® Colon Cancer, 
Genomic Health Inc., Redwood City, CA) [34] is the only test that is available outside of 
research settings, although it has not yet been recommended for clinical use.  
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This assay is based on the use of quantitative reverse transcriptase-PCR (RT-PCR) that 
measures the expression level of a subset of 12 genes, which includes seven genes for 
relapse-free survival prognosis and five reference genes that yielded a prognostic 
recurrence score (RS) [35], ranging between 0 and 100. Patients are classified into three 
categories based on their RS: low risk (RS < 30), intermediate risk (RS 30–40), or high 
risk (RS > 40). Moreover, this test reveals another parameter termed, treatment score that 
may point on the degree of benefit from adjuvant chemotherapy [35]. 
The test was based on four adjuvant studies that were conducted by the “National 
Surgical Adjuvant Breast and Bowel Project” (NSABP) and the “Cleveland Clinic 
Foundation” [36]. A validation study using archival fixed paraffin-embedded tumor 
tissue specimens from 1,436 patients with stage II colon cancer who were randomly 
assigned between adjuvant chemotherapy and surgery alone (QUASAR) confirmed the 
clinical utility of the RS score [35]. It is essential to emphasize that the test is mostly 
accurate in early stages of colorectal cancer, when a 5-FU-based chemotherapy is being 
considered. High-risk patients, as well as, patients that are candidates for other 
chemotherapeutic treatments, require further investigation [37]. 
1.1.2 Gene expression profiling to guide cancer diagnosis  
Another major area of investigation is the use of gene expression profiling for diagnosis 
in patients with cancer [38-40]. Specific gene expression profiles based on the tissue of 
origin have been identified for many tumor types. Because histogenetic information is 
maintained during metastatic process, gene expression pattern of a metastasis may reflect 
the histogenetic make-up of the primary tumour [41]. It is becoming possible to use gene 
expression-based analysis to assist in identification of the primary site [41]. Thus, several 
multigene assays have been developed for the purpose of identifying the tissue of origin 
in patients with cancer of unknown primary. 
To date, several gene expression-based tests have demonstrated the potential value of this 
approach. Although these tests use different microarray platforms, classification 
algorthims, and sample selection criteria, the overall accuracy of the confirmation of the 
primary site of origin was 75% to 89% [12, 39, 42-53]. Most of the commercially 
available tests have shown promising results in the internal validations (i.e., using same 
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specimens used for a test development) and have been translated to RT-PCR or robust 
microarray platforms [48]. However, other well identified requirements should be taken 
into account when translating and validating these tests for clinical use. According to 
guidelines for translation of genomic classifiers and for validation of clinical molecular 
tests [54-56], demonstration of reproducibility and adequate external validation analysis 
(using specimens other than those used for a test development) are required. External 
validation of a test for tumour classification needs to have a statistically valid sample 
size, inclusion of enough specimens for each tumour class to be identified, and inclusion 
of indeterminate results in overall performance [54-55]. According to these guidelines we 
will review in the following two paragraphs the publicly available evidence for each 
commercially available test.  
The Tissue of Origin (TOO) test is commercially available by Response Genetics (Los 
Angeles, CA) and clinically offered in the United States. The test is the only assay that 
has been reviewed and cleared by the Food and Drug Administration [57]. The TOO test 
compares the RNA profile (a 2000-gene profile) of a tumour FFPE specimen to 
established RNA profiles of 15 known tissues, representing 90% of all solid tumours. The 
test measures the degree of similarity between the expression patterns of the tumour and 
those of a panel of 15 different tissue types [58]. The tumour tissue types represented are 
bladder, breast, colorectal, gastric, hepatocellular, kidney, non-small cell lung, ovarian, 
pancreatic, prostate, thyroid carcinomas, melanoma, testicular germ cell tumour, non-
Hodgkin’s lymphoma, and sarcoma. The test result is presented as 15 separate similarity 
score (SS) (which are interpreted as probabilities), one for each tissue type on the panel. 
The highest SS indicates the most likely tissue of origin. Any tissue type on the panel 
with an SS of ≤5% is ruled out as a possible origin of tumour tissue with >99% 
confidence.  
The test requires an FFPE biopsy block (including block of solid tissue, cell buttons from 
fine needle aspirates, cell buttons from malignant effusions, or core needle biopsies) 
containing at least 1mm2 of tumour tissue [58]. The test can also be performed using a 
minimum of 3 unstained slides of at least 5µm-thickness from any of the biopsies 
mentioned. A minimum of 30 ng FFPE-derived RNA is sufficient to perform the test 
[58]. 
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The test was developed on a gene expression microarray (PathChip) platform that showed 
adequate reproducibility in an interlaboratory comparison study. Thus, the platform 
appears suitable for clinical application. The test was validated on independent 462 FFPE 
specimens derived from metastatic or poorly differentiated tumor specimens of known 
primary cancers and showed 89.3% accuracy in identifying tumour’s primary site [59]. 
The large number of specimens included in the external validation allowed for class 
representation of at least 25 specimens per tissue type, and inclusion of indeterminate 
results. Thus, the test appears to fulfill the criteria for successful translation outlined 
above [54-55] as was also judged by the FDA [60]. 
The first gene expression-based test for determination of the primary tumour site to be 
clinically available was the Cancer-TYPE ID test, developed by BioTheranostics as a 
laboratory-developed test (LDT). The test is an RT-PCR 92-gene assay that is reported to 
classify 39 different tumour types and 64 subtypes [11]. The test was evaluated with 
independent 119 FFPE tumour specimens and showed an overall accuracy of 86% [11]. 
However, the reproducibility of the test has not yet been adequately shown [48]. Another 
test available in the United States is the miRview mets test from Rosetta Genomics 
(Philadelphia, Pennsylvania), which is also offered as an LDT. The test is an RT-PCR 48-
microRNA (miRNA) assay that is reported to classify 25 different tumour types [49]. The 
test was evaluated in 80 independent tumour specimens (12 frozen /68 FFPE) but the 
study authors did report the overall accuracy of the confirmation of the primary site [49]. 
It is not possible to determine if the assay was successfully translated to the RT-PCR 
platform due to lack of published data, including data regarding reproducibility of the test 
[48]. The CUPrint test is a 1900-gene GEM test that was developed by Agendia BV 
(Amesterdam, The Netherlands) and is only available outside the United states in 
Agendia’s CLIA-certified laboratory. This test is reported to classify 11 different tissue 
types. Agendia did not translate the test to an RT-PCR platform but used a robust 
customized microarray instead [61].  In terms of external validation, the test was 
evaluated on an independent sample set of 84 primary and metastatic tumours 
representing 9 tumour types and showed an overall accuracy of 83% [45]. The CUP 
assay, developed by Veridex (LA Jolla, California), evaluates the expression of 10 tissue-
type specific gene markers by using quantitative RT-PCR and is designed to detect 
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tumours from 6 specific sites: lung, breast, colon, ovary, pancreas, and prostate [12, 51]. 
The test is not commercially available. The small number of genes evaluated has limited 
the number of tissues that can be distinguished by this assay. The test was evaluated with 
independent 37 FFPE tumour specimens and showed an overall accuracy of 75.6%. 50% 
of tumours outside of the 6 targeted tissue types were incorrectly assigned to 1 of these 
tissue types [48]. 
Overall, peer-reviewed evidence has shown that the quality of the external validation 
studies for these tests is insufficient [48]. These validation studies have been restricted to 
a small number of specimens and do not have adequate representation for all tumour 
tissue types being evaluated. For instance, a claim has been made of 100% sensitivity for 
a specific tissue type, with only 1 or 2 specimens for the tissue type in the validation 
sample [48]. Furthermore, data regarding specificity (i.e., how often the negative result is 
correct) are not publically available for these tests. 
Although different assays have been used, these panels appear to be accurate in 80 to 90 
percent of cases of patients using tissue from metastases in patients with known primary 
tumors [39]. Experience in patients with adenocarcinoma of unknown primary is more 
limited. The accuracy of diagnosis by molecular profiling has recently been studied 
retrospectively in a group of 20 patients who initially had CUP but subsequently had a 
primary site identified clinically [38]. The primary sites identified by the molecular 
profiling assay (from the original metastatic tumor biopsy) matched the subsequent 
clinical diagnosis in 15 of 20 patients, further supporting the value of this diagnostic 
method [38]. 
Gene expression profiling is likely to be a valuable addition to the diagnosis and 
management of patients with CUP. However, definitive demonstration of its value in 
improving treatment outcome for these patients is not available. Ongoing clinical trials 
are evaluating the efficacy of treatment directed by RT-PCR assay results, as well as 
comparing the utility of the several available assays. 
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1.1.3 Obstacles to incorporating gene expression profiling 
in clinical practice 
Using these gene expression profiling tests in clinical oncology poses several questions: 
How convincing is the data? Most companies support their claims about these tests, 
which cost from about $3,000 to more than $5,000 per patient, with data from 
retrospective analyses rather than prospective trials. Large ongoing trials for some of 
these tests may increase practitioners’ comfort with them, but final data are years away 
and a funding decision may need to be made prior to having full efficacy or effectiveness 
data of these gene expression applications. Thus, reimbursement policies and clinical 
validation are still the main obstacles for personalized medicine in oncology. The impact 
of these innovations on health and economic outcomes, if introduced into general 
practice, has not yet been determined. As these tests are expensive there are important 
tradeoffs to consider in deciding whether to adopt these tests in a resource constrained 
system such as the Canadian health care system. 
 
1.2 Cost Effectiveness Analysis 
Cost effectiveness analysis (CEA) is a commonly used technique to assess the “value-for-
money” of new medical technologies such as drugs, devices, policies, medical 
procedures. For a given level of resources available, society or decision maker wishes to 
maximize the total aggregate health benefit conferred [62]. International decision making 
bodies such as the National Institutes for Health and Clinical Excellence (NICE) in the 
United Kingdom (UK) [63] and the Pharmaceutical Benefits Advisory Committee 
(PBAC) in Australia [64] have formally incorporated CEA into their processes for 
reviewing new medical technologies and inform health technology adoption decisions 
[65]. Similarly, the Common Drug Review (CDR) in Canada [66] considers CEA when 
considering reimbursement of new pharmaceuticals. 
CEA involves a formal comparison of the incremental costs and incremental benefits 
associated with incorporating a new medical technology into an existing standard of care. 
Costs are expressed in currency units, and benefits are expressed in common units such 
as life expectancy (i.e., “life years gained”). The frequent use of “life year gained” which 
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has been used as the chief outcome variable in CEA is considerably restrictive. CEA 
produces a more robust and meaningful outcome measure by combining the quality and 
quantity of the outcomes [67]. Therefore, Quality Adjusted Life Year (QALY) has 
become a common metric in CEA. QALYs are life years that have been adjusted by a 
value between 0 and 1 to reflect difference in quality of life for difference health 
conditions. Results of a CEA are usually presented in the form of a ratio called the 
incremental cost-effectiveness ratio (ICER) where the ICER associated with 
incorporating a new medical technology is given as by:  
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Because CEA involves marginal cost and benefits, the choice of which current standard 
of care or technology to compare can drive the calculation and the conclusion of a CEA 
(i.e., an appropriate definition for “Current” in the ICER equation). Therefore, CEA is 
very sensitive to the choice of strategies being compared. The new medical technology is 
then considered “cost-effective” based on a value judgment (what cost is considered a 
good price for an additional outcome) [68]. Several heuristics are commonly used to 
assist in making this value judgment including plotting the incremental cost and 
effectiveness in a cost-effectiveness plane [69] comparisons with other technologies in a 
league table [70] and comparisons with pre-specified thresholds (e.g., £30,000 / QALY 
gained in UK [71] or $100,000 / QALY gained in Canada [62, 72]). 
 
1.2.1 Models and parameterization in CEA 
There are two common approaches for parameterization in CEA of a new medical 
intervention. In the first, data for CEA are estimated directly from a single clinical trial 
(i.e., use of resources are collected concurrently with the clinical trial). In this case, the 
economic data can be viewed as experimental and are typically analyzed in the same way 
as the clinical data. In the second approach, decision analytic models (e.g., decision trees, 
Markov models, and Monte Carlo simulation models [73]) are used and data from a 
number of sources are synthesized [74]. The data for this type of CEA could be a mix of 
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experimental (e.g., efficacy data from randomized clinical trials), observational (e.g., 
resource-use data extracted from patient chart review or a claims database), routine 
statistics (e.g., data delineating the unit costs or prices of resources), local surveys (e.g., 
data showing how therapies effect patients’ quality of life), or expert opinions (e.g., data 
describing the physical quantities of resources consumed by the strategies being 
compared). Even randomized clinical trial-based CEAs often use some data obtained 
from outside the clinical trial, such as the prices (or unit costs) of health care resources. 
It has been argued that CEAs using experimental data are the most internally valid and 
meet the biostatistical and epidemiological rules, in that the differences between medical 
interventions being compared are unlikely to be biased [74]. However, several factors 
may still limit the internal and external validity of experimental data and consequently 
the results from CEAs using these data. 
Clinical trials usually include only a small fraction of the targeted general population. 
Thus, the experience of participants in these trials may not reflect the experience of the 
targeted general population [75-76]. Studies have suggested that the observed effects in 
these trials may not necessary reflect the effects of the treatments or technologies under 
investigation [77-78]. Clinical trials are usually of limited duration of follow up relative 
to the possible duration of impact of the alternatives. In addition, many CEA guidelines 
call for use of a “lifetime” horizon. This set of factors necessitates extrapolation of 
clinical trial data when used in cost-effectiveness analyses using models (e.g. Markov 
chain simulation) to assess the long-term impact of the alternative treatment options on 
cost and effectiveness [79]. Moreover, there are circumstances where randomization may 
not be possible such as studies aiming to investigate the impact of adherence to drug 
treatmenton clinical outcomes in real-world settings. 
A modeling-based CEA offers the potential for generalization and for transferring the 
results to other settings. However, clinical (both experimental or observational) and 
economic data reported in the literature and commonly used in these analyses, may not be 
entirely relevant to the population in the studied geographic region and setting in which 
alternatives are likely to be applied in the real world [80]. Ultimately, data used in CEAs 
should be extracted from settings that accommodate socioeconomic variability and are 
likely to reflect regular clinical and economic experience of the relevant patient 
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population under investigation in the studied geographic region with long follow up 
periods [81]. 
Disease registries and administrative health databases can be valuable clinical and 
economic data sources for conducting CEAs [82]. These databases contain records of 
events that have occurred under everyday conditions. The main advantage of using these 
databases is that interventions or technologies studied in CEAs can be described under 
actual “real world” conditions that are relevant to the studied geographic region [81].The 
alternative is to use literature from clinical trials or observational studies data. These 
databases are often population based (i.e., minimizing selection bias), have high rates of 
disease ascertainment (i.e., disease prevalence and incidence), and include a large-enough 
population over a long-enough time period to evaluate effectiveness and costs among 
different age- or race-specific population subgroups [83-84]. 
1.2.2 Administrative health data in Canada 
1.2.2.1 Provincial administrative health databases 
In Canada, provincial governments are generally responsible for the funding of inpatient 
and outpatient hospital services and physician services (Table 1) as per the Canada 
Health Act [85]. In addition, some provincial governments fund other services such as 
non-physician professional services (e.g. chiropractic, optometry), prescription drugs 
(i.e., with eligibility criteria), vaccines, home care, and long-term care. Each provincial 
government maintains records of utilization for most of these services. The maintenance 
of these records forms the provincial administrative health databases (Table 1). 
In addition, each province maintains a population registry where each resident is assigned 
a unique identifier (scrambled ID) which is often in the form of a health plan number 
(health insurance number). For example in Ontario, the unique identifier is the Ontario 
Health Insurance Plan (OHIP) number. This unique identifier is used to record each 
service in the provincial databases. Via the unique identifier, an analyst can link available 
records for drugs, physician visits, hospital discharges, and some outpatient visits to form 
a unique patient record. This record could include all information for all the patient’s 
services. 
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Linkage is useful because it allows analysts to identify patients with specific 
characteristics in one database, and then gather additional information about those 
patients using other databases. For example, patients who received hospital-based and 
community-based emergency and ambulatory care can be identified in Ontario using the 
National Ambulatory Care Reporting System (NACRS) and then get their OHIP billing 
claims before and after.  
1.2.2.2 National administrative health databases 
The Canadian Institute for Health Information (CIHI) facilitates the development and 
maintenance of an integrated health information system at a national level. In particular, 
CIHI, in co-operation with the provincial governments, develops data standards for some 
databases such as inpatient care, ambulatory care, and pharmaceuticals. The provinces 
maintain their own data systems which may be more complete than the requirements 
specified by CIHI, and submit their patient or client data on hospital care and physician 
care to CIHI using the CIHI standards on a quarterly or annual basis. 
The CIHI databases are most useful when one wants to obtain data on overall counts of 
services and on overall costs without identifying how many people have received these 
services. CIHI does have unique identifiers, but they do not have population registry data. 
Unique identification is not always accessible to researchers outside CIHI, whereas some 
provinces (Manitoba, Quebec, and Ontario in particular) have a long history of successful 
research collaboration with academics. 
 
1.2.2.3 Disease registries  
Disease registries are surveillance systems which maintain records of patterns of medical 
history, diagnostics or treatment in patients with a specific disease and follow outcomes 
or survival patterns over time. In Canada, patients are often identified using the same 
unique identifiers used in the population registry. This allows researchers to link disease 
registries with administrative databases to build detailed longitudinal records of their 
treatments and health care utilization. 
There are several disease registries in Canada. However, the most well established are the 
cancer registries. These cover the entire population, with all provincial and territorial 
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registries reporting to the Canadian Cancer Registry (CCR). The overall coverage for 
cancer incidence data is estimated to be at least 95% [86]. Although these registries differ 
somewhat in their approaches and methods, their procedures for registration are fairly 
consistent, and comparable surveillance data from each province are reported up to the 
CCR level. 
There are other disease registries in Canada that have also instituted surveillance 
operations and built databases of patients with specific diseases. The Canadian Organ 
Replacement Registry, managed by CIHI, organizes organ replacement and end stage 
renal failure records for all 84 organ replacement centers across the country. Starting in 
May 2001, the Canadian Joint Replacement Registry (CJRR), managed by CIHI and 
orthopedic surgeons, collects information on hip and knee joint replacements performed 
in Canada. The CJRR follows joint replacement patients over time to monitor their 
revision rates and outcomes. The Canadian Trauma Registry has accommodated the 
records of all Ontario accidental injuries and is currently expanding to cover all Canada. 
In addition, the Institute for Clinical Evaluative Sciences (ICES) has recently received 
Canadian Institute for Health Research (CIHR) funding to develop a Canadian stroke 
registry. 
 
1.2.3 Use of administrative health data for descriptive 
costing studies 
In Canada, analysts can use the information in health administrative databases to describe 
the health care utilization and direct costs that are associated with persons with specific 
medical conditions or who use specific drugs or services. The utility of administrative 
data for descriptive costing has been demonstrated in a number of analyses. For example, 
Krahn et al. [87] used the Ontario Cancer Registry, Discharge Abstract Database, Claims 
History Database of the OHIP, National Ambulatory Care Reporting System and other 
administrative databases in Ontario to estimate the total healthcare costs and costs 
attributable to prostate cancer across all stages of disease. Another analysis by Carriere et 
al. [88] used the Canadian Institute for Health Information’s Inpatient Discharge Abstract 
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Database for the province of Alberta and Alberta Health Insurance Plan Registry to 
determine the cost per day for the treatment of community-acquired pneumonia. 
1.2.3.1 Case definition  
When using administrative data to estimate cost of health care utilization of disease (i.e., 
cost of illness) the analyst must first develop criteria to identify the patient population of 
interest. For instance, Blanchard et al. [89] developed such criteria for identifying 
diabetes cases using Manitoba administrative data. Blanchard et al. [89] defined a 
diabetes case as a patient record with two or more diabetes diagnoses at different visits in 
the physician billings data during a two-year period or one diagnosis in the hospital 
inpatient data. Another analysis by Simpson et al. [90] used an expanded definition with 
Saskatchewan administrative data to measure costs during a 10-year period for persons 
who had no previous diabetes records. In that definition, the dispensing of insulin or an 
oral antidiabetic drug was added to the list of possible indications. In case of a narrower 
target patient population of interest (i.e., persons with diabetes who have nephropathy) 
the analyst must develop a more detailed algorithm to define the disease. For example, 
Bernstein [91] used Manitoba administrative data and developed a case definition for 
inflammatory bowel disease (IBD). Bernstein [91] defined a case as IBD if the physician 
billing records showed at least five physician visits that were coded as IBD during any 
time span that was greater than two years. When cases with specific medical conditions 
of interest are captured by disease registries, the analyst may use data captured by these 
registries to identify those cases. For instance, a recent analysis by Oliveira et al. [92] 
used the Ontario Cancer Registry to identify patients diagnosed with the 21 most 
common cancer sites in Ontario. After identifying the patient population of interest, the 
analyst can take an incidence approach or prevalence approach for costing of illness 
using administrative data. 
1.2.3.2 Incidence approach for costing of illness 
 The incidence approach allows analysts to track costs (i.e., longitudinal costing) from the 
time when the disease is diagnosed until a desired end point (e.g., cure, disease 
progression, or death). For a chronic disease, the tracking may require years of 
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observation. For instance, Johnston et al. [93] measured the cost of hospital, physician, 
and drug services for persons with diabetes, for 10 years from the time of incidence.  
Analysts may find the incidence approach to be useful in determining cost of resource use 
that is avoided because of cases that avoided. This approach would be useful in particular 
to planners who want to determine the economic impact of a preventive measure. 
Analysts may also find the incidence approach for costing to be useful in examining the 
impact of disease severity at diagnosis on health care utilization and costs. For instance, 
Mittman et al. [94] used the Ontario Cancer Registry to identify incident cases of 
colorectal cancer and obtained information about colorectal cancer stage at diagnosis. 
Mittman et al [94] linked those cases with the Home Care Administration database and 
the Registered Persons Database to estimate the cost of home care services over the 
patient observation time by stage of colorectal cancer at diagnosis. Importantly, the 
incidence approach for costing has been useful in examining the impact of the phase of 
care on health care utilization and costs.  
In the phase-based costing approach to costing, the analyst divides the patient’s follow up 
time to discrete phases. The time frame for each phase should be defined and a hierarchy 
of time frames should be specified when necessary so that all phases stay mutually 
exclusive. In 2013, Oliveira et al. [92] used a phase-based approach to examine the costs 
of health care incurred before and after cancer diagnosis. Oliveira [92] used the Ontario 
Cancer Registry and Ontario administrative data to identify incident cases of cancer. 
Patient’s observation time was divided into two discrete periods: the pre-diagnosis phase 
and initial care phase. The pre-diagnosis phase was defined as the 3 months before 
diagnosis. The initial care phase included the date of diagnosis and the subsequent 12 
months. Recently, Mittmann el al. [94] used a phase-based costing approach to costing 
home care services for incident cases with colorectal cancer in Ontario. Mittman et al. 
[94] divided the time horizon following diagnosis into three discrete care phases: initial, 
continuing, and terminal. The initial care phase was defined as the first 6 months 
following the diagnosis of colorectal cancer. The terminal care phase was defined as the 6 
months before death and applied to patients who died during follow-up period. The 
continuing care phase was defined as the time between the initial and terminal phases. 
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The following hierarchy of time frames was used: terminal care> initial care> continuing 
care, such that all phases were mutually exclusive. 
1.2.3.3 Prevalence approach for costing of illness 
The prevalence approach focuses on the costs of all cases with the disease during a fixed 
period (e.g., a year). Using this approach, the analyst will include all cases with the 
diagnosis, even if the incidence of the disease occurred in a prior year. Jacobs et al. [95] 
used the prevalence approach to calculate the direct medical care costs of diabetes using 
administrative databases from Manitoba. Jacobs et al. [95] studied the net (i.e., 
attributable costs) by subtracting the costs per person with diabetes from the per-person 
costs of the non-diabetic population.  Simpson et al. [90] used the same approach to 
estimate direct medical care cost of diabetes using administrative databases from 
Saskatchewan. However, Simpson et al. [90] used diagnostic codes to identify services 
that were related to the diagnoses of diabetes.  
1.2.4 Use of administrative health data in CEA 
Despite the potential advantages from disease registries and administrative health data in 
CEAs, the use of these data to conduct CEAs in Canada is relatively uncommon. In one 
of the first economic evaluations using Canadian administrative data, Brown MG [96] 
studied the cost-effectiveness of New Brunswick’s Extra-Mural Hospital (EMH) home 
health care program using population-based administrative data on physician services 
utilization to examine whether home care services act indirectly as substitutes for 
physician services. Brown MG suggested that the introduction and expansion of New 
Brunswick’s EMH home health care program have unanticipated substitution effects, 
which reduce health system costs by reducing the rate of growth of per-capita utilization 
of physician services. 
In another analysis, Najafzadeh et al [97] studied the cost-effectiveness of herpes zoster 
(HZ) vaccine versus status quo (no HZ vaccine) from the perspective of the Canadian 
healthcare payer. They estimated health resource utilization using administrative data 
retrieved from the British Colombia from 1994 to 2003. They reported an ICER of 
41,709 per QALY gained for a cohort of elderly subjects aged  ≥ 60 years and concluded 
that HZ vaccination of adults, specially  for individuals aged 60-70 years, seems to be a 
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cost-effective intervention and might be considered by Canadian decision makers. 
Recently, Sander et al [98] reported an economic evaluation of Ontario’s universal 
influenza immunization program (UIIP) compared to a targeted influenza immunization 
program (TIIP) using Ontario health administrative data. They estimated an ICER of 
10,797 per QALY gained and concluded that the UIIP compared TIIP is an economically 
attractive intervention. 
1.2.5 Decision Analytic Models and Cost Effectiveness 
Analysis in Oncology 
Decision analytic models have been used extensively to evaluate health technologies 
related to oncology. Examples include cost effectiveness analyses of preventive strategies 
for women with BRCA1 or BRCA2 mutations [99]; HER testing and trastuzumab 
treatment for breast cancer [100]; the cost effectiveness of various strategies for screening 
for colorectal cancer [101-104]; the cost effectiveness of different treatment options for 
prostate cancer [105-106]; and cost effectiveness analyses of specific drugs [107-110]. 
This represents a portion of work in the area. Searches of common medical databases for 
terms related to cost effectiveness analysis and oncology yield thousands of results. 
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Chapter 2  
2 Objectives and research framework 
I aimed to conduct an economic evaluation of potential application of major gene 
expression profiling assays in breast cancer and cancer of unknown primary for the 
purpose of determining whether these applications represent value for money from the 
perspective of the Canadian health care system. The research proceeded with the 
following steps: 
• Develop decision-analytic models. These models include decision trees with several 
Markov models as the terminal nodes in the trees. Markov models are used to 
simulate cancer progression correspondent with certain disease severity or different 
types of cancer. 
• Fit models parameters using three main sources of information: Manitoba Cancer 
Registry, Manitoba health administrative databases, and use of secondary sources and 
the existing literature to estimate some additional models parameters of interest, such 
as quality of life for various health states and sensitivity and specificity of molecular 
profiling assays.  
• Set the models to perform cost effectiveness analyses of different molecular profiling 
assays. The cost-effectiveness analyses are conducted according to recommendations 
by the Canadian Agency for Drugs and Technologies in Health [111]. Results are 
presented in the form of ICER which provides a measure of average cost per 
additional unit of health benefit. Outcomes for health effects are measured in QALYs 
(i.e., life-years weighted by utility estimates to produce QALYs). Cost outcomes are 
measured as the mean cost per patient. 
• Conduct one-, two- and three-way deterministic sensitivity analyses on parameters of 
interests to characterize uncertainty in the output measures and determine the 
minimum conditions in terms of cost and accuracy for which these molecular 
profiling assays would be cost effective. This helps to provide insights about the 
potential economic attractiveness of assays that are still in various stages of 
development and regulatory approval. 
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•  Conduct probabilistic sensitivity analysis using Monte Carlo simulation to 
understand the robustness of the results. Each iteration consists of a random draw 
from an appropriate distribution for all model inputs to produce a distribution of 
model outputs. 
• Conduct value-of-information analysis [112] as part of the sensitivity analysis to 
determine the expected monetary value of perfect information about these molecular 
profiling assays in the Canadian setting. In particular, baseline decision models are set 
up to express molecular profiling assay related parameters (i.e., sensitivity and 
specificity of the assay) as probability distributions (i.e., reflecting uncertainty of that 
assay in the Canadian setting) on the basis of available validation analyses and the 
entire model is set up as a probabilistic model. Using simulation techniques (i.e., 
making random draws of the probabilistic model), the level of uncertainty in the 
model is assessed. Using a willingness to pay threshold [69], the opportunity cost 
associated with the choice of a molecular profiling assay as the optimal strategy is 
calculated and presented as a total of expected value of perfect information (EVPI) 
about a given assay per patient. Using the size of patient population, the EVPI about a 
gene expression profiling assay is calculated for the entire target population that could 
potentially benefit from more research on the predictive value of that assay in the 
Canadian setting. The EVPI provides decision makers with valuable information 
about the use of novel funding models such as conditional funding alongside a field 
evaluation [113]. 
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Chapter 3  
3 Cost-effectiveness of a 21-gene recurrence score 
assay versus Canadian clinical practice in women with 
early-stage estrogen- or progesterone-receptor-
positive, axillary lymph-node negative breast cancer 
3.1 Abstract 
A 21-gene recurrence score (RS) assay may inform adjuvant systematic treatment 
decisions in women with early stage breast cancer. I sought to investigate the cost 
effectiveness of using the RS-assay versus current clinical practice (CCP) in women with 
early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative 
breast cancer (ER+/ PR+ LN- ESBC)from the perspective of the Canadian public 
healthcare system. I developed a Markov model to project the lifetime clinical and 
economic consequences of ESBC. I evaluated adjuvant therapy separately in post- and 
pre-menopausal women with ER+/ PR+ LN- ESBC. I assumed that the RS-assay would 
reclassify pre- and post-menopausal women among risk levels (low, intermediate and 
high) and guide adjuvant systematic treatment decisions. The model was parameterized 
using 7 year follow up data from the Manitoba Cancer Registry, cost data from Manitoba 
administrative databases, and secondary sources. Costs are presented in 2010 CAD. 
Future costs and benefits were discounted at 5%.The RS-assay compared to CCP 
generated cost-savings in pre-menopausal women and had an ICER of $60,000 per 
QALY gained in post-menopausal women. The cost effectiveness was most sensitive to 
the proportion of women classified as intermediate risk by the RS-assay who receive 
adjuvant chemotherapy and the risk of relapse in the RS-assay model. The RS-assay is 
likely to be cost effective in the Canadian healthcare system and should be considered for 
adoption in women with ER+/ PR+ LN- ESBC. However, ongoing assessment and 
validation of the assay in real-world clinical practice is warranted. 
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3.2 Introduction 
In 2011, an estimated 23,200 women in Canada will be diagnosed with breast cancer 
[114]. Approximately half of them will be diagnosed with early-stage estrogen- or 
progesterone-receptor-positive, axillary lymph-node negative breast cancer (ER+/ PR+ 
LN- ESBC) [115]. Standard care for these patients usually includes local therapy (surgery 
with or without radiation) followed by adjuvant systematic therapy such as endocrine 
therapy alone (tamoxifen or aromatase inhibitors) or chemotherapy followed by 
endocrine therapy [116]. Canadian guidelines specify that a patient’s risk of recurrence 
can be classified as low, intermediate or high and that adjuvant chemotherapy may be 
added when the benefits of treatment outweigh toxicities of therapy [117]. However, 
evaluating the risks and benefits of chemotherapy based on the Canadian guidelines is 
difficult because the histopathologic measures that inform the guidelines are not accurate 
predictors of risk or benefits of chemotherapy [18, 117-120]. A validated software 
program Adjuvant!Online (AOL) has been developed  that  projects outcomes at 10 years 
to assist oncologists in adjuvant decision-making process. However, AOL is also based 
on histopathologic measures. 
The 21-gene recurrence score assay (Oncotype DX) produces a “tumor signature” 
reflecting tumor biology and risk of relapse [11, 18]. An algorithm produces a continuous 
variable known as the “recurrence score” (RS) reflecting prognosis, which ranges from 1 
(lower risk) to 100 (higher risk), based on the expressions of the 21 genes isolated from 
tumor samples. Women with a score of less than 18 have a low risk of recurrence and 
typically have good outcomes from endocrine therapy alone, whereas those with a score 
of 31 or more have a high risk of recurrence and gain the largest expected benefit from 
the addition of chemotherapy to endocrine therapy. Women with a score between 18 and 
30 have an intermediate risk and do not appear to have a large benefit from chemotherapy 
but the uncertainty in the estimate cannot exclude a clinically important benefit [11, 25]. 
The prognostic and predictive value of the RS-assay in women with ER+/PR+ LN- 
ESBCwas evaluated in retrospective analyses of the National Surgical Adjuvant Breast 
and Bowel Project (NSABP) chemotherapy-tamoxifen trials (B-14 and B-20) [11, 18, 
24 
 
121] in the United States. It was shown that among ER+/PR+ LN- ESBC patients, 
approximately, 51% had a low RS, 22% an intermediate RS, and 27% a high RS [11, 18, 
121]. The assay was found to be more accurate than histological measures alone in 
predicting the likelihood of breast cancer recurrence (both loco-regional [121] and distant 
recurrence [11, 18]) and patient survival within 10 years of initial diagnosis [11], as well 
as benefit from adjuvant chemotherapy [11, 121]. Additionally, clinical significance of 
the RS-assay has been reported in the Asian population [81]. 
In 2007 the RS-assay was recommended in the National Comprehensive Cancer Network 
and American Society for Clinical Oncology guidelines as “evidence-based” to guide the 
use of adjuvant chemotherapy in all women with ER+/ PR+ LN- ESBC [122-123]. Public 
coverage of the 21-gene assay is limited and inconsistent across Canada. However, the 
use of the test with reimbursement mechanisms is likely increasing. It is available in 
Ontario through “out-of-country health services” which requires a request from an 
oncologist and pre-approval [124-125]. In 2010 the Ontario Health Technology Advisory 
Committee (OHTAC) recommended that the assay be made available “within the context 
of a field evaluation” [126]. It is also available in a limited fashion in British Columbia 
and Quebec [125]. The test is not widely used and in 2010 less than 1000 patients 
received the test across Canada [125] but few field evaluations to establish its impact on 
Canadian practice are ongoing in British Columbia and Ontario.  
According to the Annual Report Card of the Cancer Advocacy Coalition of Canada, the 
RS-assay will cost $CAD 4,000 per patient including all Canadian system expenses 
[124]. Previous cost-effectiveness analyses of the RS-assay in women with ER+/ PR+ 
LN- ESBC in the US [127-128], Japan [129-130], Israel [131] and Canada [132-134] 
suggested that it is likely to be cost saving or cost effective in this patient group. 
However, findings from studies in Israel [131] and Japan [19-20] cannot be extrapolated 
to the Canadian context because of possible variations in clinical practice and different 
approaches to pricing and reimbursement.  Additionally, analyses from the US [127-128] 
and Canada [132-134] did not use all relevant data and suffer from other limitations as 
indicated elsewhere [135]. 
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Generation of recommendations for Canadian clinical practice guidelines regarding the 
use of RS-assay requires a comprehensive health economic evaluation of the assay in the 
Canadian setting. The purpose of this study was to conduct a cost-effectiveness analysis 
of the RS-assay versus current clinical practice (CCP) regarding adjuvant chemotherapy 
treatment in women with ER+/ PR+ LN- ESBC from the perspective of the Canadian 
healthcare system. 
3.3 Methods 
3.3.1 Overview of Model-Structure 
I developed a decision analytic model (Figure 1) to project the lifetime clinical and 
economic consequences of ER+/ PR+ LN- ESBC under two different treatment 
strategies. The model begins with a decision to use the RS-assay or to continue with CCP 
(Figure 1a). I assumed that each strategy (RS or CCP) classifies patients to three risk 
levels (low, intermediate and high) and corresponding treatment regimens (endocrine 
therapy plus chemotherapy or endocrine therapy alone). Patients receiving endocrine 
therapy alone entered model “E” (Figure 1b) and those receiving chemotherapy plus 
endocrine therapy entered model “C” (Figure 1c). 
Model “E” simulated monthly transitions among the following four distinct health states: 
(1) remission; (2) loco-regional recurrence (LR); (3) distant recurrence (DR); (4) death. 
Model “C” simulated monthly transitions among the following five distinct health states: 
(1) remission with no chemotherapy-related serious adverse effects (CSAE); (2) 
remission with CSAE; (3) LR; (4) DR; (5) death. 
I used a lifetime horizon and half cycle correction [136]. Future costs and benefits were 
discounted at 5% annually following Canadian guidelines [72]. Data collection and 
analysis involving Manitoba administrative databases (including the Manitoba Cancer 
Registry, the Hospital Discharge Database, the Physician Claims Database and the Drug 
Program Information Network) were approved by the University of Manitoba Health 
Research Ethics Board. 
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Figure 1. Decision model for early stage breast cancer. 
a  RS-assay versus Canadian clinical practice±. 
 
b Schematic representation of the Markov model structure “E”*‡. 
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c  Schematic representation of the Markov model structure “C”†‡. 
 
±  The risk classification criteria in the Canadian clinical practice arm was based on the Canadian clinical practice 
guidelines for adjuvant systemic therapy for women with node-negative breast cancer [117].  
* Patients entering Markov model “E” start the model and remain in the remission state unless they relapse (LR, DR or 
Dead).  
† Patients entering Markov model “C” start the model in the remission state with no CSAE. Within the first cycle patients 
may develop CSAE. These patients will make a transition to the remission state with CSAE. During the first cycle, 
patients also may transition to DR, LR and Dead states. After the first cycle, patients may remain in the two remission 
states unless they relapse in to LR, DR or Dead.  
‡ In both Markov models, patients who developed LR, remain in the LR state or make transition to DR or Dead states. 
Patients who developed DR remain in the DR state or make transition to the Dead state. The cycle length was 1 month. 
LR, loco-regional recurrence; DR, distant recurrence; CSAE, chemotherapy-related serious adverse effects.  
DR 
Dead 
Remission with 
no CSAE 
LR 
Remission with 
CSAE 
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3.3.2 Risk distribution and transition probabilities 
The Manitoba Cancer Registry is a provincial database that contains records for more 
than 99.5% of all cancer patients in Manitoba [137]. Information on breast cancer 
staging, based on the American Joint Commission on Cancer (version 5), has been 
collected for breast cancers diagnosed since January 1995 [138]. I used the Registry to 
identify a study cohort consisting of all pre-menopausal (defined as age <50 years) and 
post-menopausal (age ≥50 years) women living in Manitoba diagnosed with ER+/ PR+ 
LN- ESBC (stage I/II) during the period from January 1, 2000 to December 31, 
2002.Although data on human epidermal growth factor receptor 2 (HER-2) status were 
not collected by the registry during this time frame, the majority of these women are 
likely HER-2 negative since women with HER-2 positive are only found in 
approximately 10% to 15% of endocrine positive breast cancers such as those in our 
study population [139-143]. I used data from women diagnosed during this period so that 
a long follow up period would be available. Seven-year follow-up information from the 
time of diagnosis was available for each patient. This included breast cancer recurrence 
(LR and DR) and treatments (surgery, radiation therapy, endocrine therapy and 
chemotherapy). I linked the study cohort identified using the Registry with administrative 
data held by Manitoba Health and Healthy Living including the Hospital Discharge 
Database, the Physician Claims Database and the Drug Program Information Network. 
To protect confidentiality, the linkage in this study was performed, via scrambled health 
number, using anonymatized versions of these databases. 
To verify that the proportion of women who received adjuvant chemotherapy in our study 
cohort would reflect more recent clinical practice regarding adjuvant chemotherapy 
administration, I examined a second cohort, consisting of all women diagnosed between 
January 1, 2003 and December 31, 2005. I did not find the proportion receiving adjuvant 
chemotherapy to differ between the two time periods (chi-square test, level of 
significance of 0.05) and thus used the earlier time period with longer follow-up data to 
parameterize the model. 
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For the CCP model I estimated the risk distribution and proportion receiving 
chemotherapy within each risk level (Table 1). According to the Canadian clinical 
practice guidelines, risk can be specified on the basis of tumor size, histological or 
nuclear grade, and lymphatic and vascular invasion [117]. The Manitoba Cancer Registry 
collects this information with the exception of lymphatic and vascular invasion. Given 
the significant correlation between tumor size and lymphatic and vascular invasion[144], 
I classified pre- and post-menopausal women for this analysis as belonging to three risk 
levels (low, intermediate and high risk) on the basis of tumor size and histological or 
nuclear grade only. I defined current clinical practice according to the observed 
administration of adjuvant therapy in the ER+/ PR+ LN- ESBC cohort during the study 
period. I conducted survival analyses using Kaplan-Meier estimates for pre- and post-
menopausal women separately, stratified by use of adjuvant chemotherapy, using 7 years 
of follow up data from the Manitoba Cancer Registry, and used this information to 
estimate all transition probabilities in the CCP Markov models. 
For the RS-assay model, I derived the risk distribution and monthly transition 
probabilities from remission to LR, DR and Death over 10 years within each risk level 
from retrospective analyses of the NSABP chemotherapy-tamoxifen trials (B-14 and B-
20) (Table 1) [11, 121]. Investigators from the B-14 and B-20 studies provided Kaplan 
Meier curves for LR, DR and death events stratified by risk level. To account for 
menopausal status, I adjusted all transition probabilities derived from these summary 
statistics based on corresponding risk ratios (for LR, DR and death) comparing pre- to 
post-menopausal women derived from our studied ESBC cohort. The risk ratios were 
weighted using the menopausal status balance reported in the B-14 and B-20 trials [11, 
121]. 
There is still uncertainty as to whether chemotherapy is necessary for women with 
intermediate risk. Reported usage in this group varies, including estimates of 56% [145], 
50% [146], 47% [147], 38% [148], 33% [131], and 26% [149]. In the base case I 
assumed that 50% of women in the intermediate risk group would receive adjuvant 
chemotherapy. 
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There is no data suggesting that outcomes after first relapse are affected by the primary 
adjuvant therapy received [150]. Thus, I assumed that transition probabilities following 
first relapse in the RS-assay model would be the same as those in the CCP model. 
To extrapolate beyond the follow-up period of the ESBC cohort and the clinical trials 
used for this study, I assumed that the observed average monthly transition probabilities 
from remission to LR, DR and Death during the last observed year of follow-up would be 
constant over the extrapolated lifetime. I used female age-adjusted life tables for 
Manitoba to adjust the probabilities from remission to death in order to account for the 
incremental mortality risk over the extrapolated time [151]. 
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Table 1. Parameter estimates and sources. 
 
Variables 
Pre-menopausal 
Women 
Post-menopausal 
Women 
Duration Distribution 
used in PSA† Source Base 
case 
value 
Range tested 
in sensitivity 
analyses 
Base 
case 
value 
Range tested 
in sensitivity 
analyses 
Risk classification by CCP (%)        
  High risk 21.1 15.8 – 32.6 22.3 18 – 27  Dirichlet MCR 
    Chemotherapy-treated women  100 85.1 – 100 53.8 43 – 64.4  Beta MCR and PC 
  Intermediate risk                                                      72.6 62.9 – 80.6 52.3 47 – 57.5  Dirichlet MCR 
    Chemotherapy-treated women 65.2 53.4 – 75.4 14.2 9.9 – 20  Beta MCR and PC 
Low risk 6.3 0 – 10 25.4 21.2 – 30.2  Dirichlet MCR 
Chemotherapy-treated women                                16.7 10 – 20 3.4 0 – 10  Beta MCR and PC 
Overall chemotherapy-treated women by CCP (%) 69 60 – 83 19 13 – 27.7   MCR and PC 
Risk classification by RS-assay (%)        
High risk 27.7 22.9– 33.1 23.1 18.7 – 28.3  Dirichlet [11] 
Chemotherapy-treated women  100 90 – 100 100 90 – 100  Beta [11] 
Intermediate risk                                                      19.5 15.4 – 24.4 21.5 17.1 – 26.5  Dirichlet [11] 
Chemotherapy-treated women 50 0 – 100 50 0 – 100  Beta [131, 148-149, 152] 
Low risk 52.6 46.9 – 58.3 55.4 49.7 – 61  Dirichlet [11] 
Chemotherapy-treated women 0 0 – 10 0 0 – 10  Beta [11] 
Overall chemotherapy-treated women by RS-assay (%)                                                                        37.5 30 – 47.8 33.8 27 – 44.3   [11, 131, 148-149, 152] 
Chemotherapy-related serious adverse effects (%) 2.5 0 – 10.6 4 0 – 12.3  Beta MCR and HA 
Health-State Utilities‡        
Remission state        
Remission on chemotherapy regimen with 
minor or no toxicity 0.85 -20% 0.783 -20% 6 months Beta [153-155] 
    Remission on chemotherapy regimen with 0.623 -20% 0.577 -20% 6 months Beta [153-155] 
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major toxicity 
    Remission after chemotherapy regimen 0.872 -20% 0.808 -20% Life Beta [155-156] 
    Remission on hormonal therapy 0.881 -10% – +10% 0.816 -10% – +10% 60 months Beta [153-155] 
    Remission after hormonal therapy 0.89 -10% – +10% 0.824 -10% – +10% Life Beta [153-155] 
Loco-regional recurrence, under treatment 0.623 -10% – +10% 0.577 -10% – +10% 12 month Beta [150, 153-155] 
Loco-regional recurrence, after treatment 0.757 -10% – +10% 0.700 -10% – +10% Life time Beta [150, 153-155] 
Distant recurrence 0.445 -10% – +10% 0.412 -10% – +10% Life time Beta [150, 153-155] 
Death state 0  0     
Cost associated with remission (per month), $         
First year after diagnosis with ESBC        
Cost of surgerya 3390 3000 – 3780 3642 3384 – 3900 One time LogNormal PC. HA and CL 
    Cost of radiation therapyb 3410 2737 – 4252 3027 2430 – 3776 One time LogNormal PC and CL 
    Cost of endocrine therapyc        
Tamoxifen 12.4 11.6 – 13.2 12.4 11.6 – 13.2 12 months LogNormal DPIN 
      Aromatase inhibitors   156 120 – 193 12 months LogNormal DPIN 
      Aromatase +tamoxifen   72 62 – 81 12 months LogNormal DPIN 
    Cost of chemotherapyd        
Nursing, overhead and administration costs  317.6  317.6  During 
chemotherapy LogNormal CL 
      Related physician costs  23.4 21.5 – 25.2 23.4 21.5 – 25.2 During 
chemotherapy LogNormal PC 
      Chemotherapy regimen options         
CMF 478  823  5 months LogNormal MCR 
 AC 806  1918  3 months LogNormal MCR 
        FAC 924  1270  5 months LogNormal MCR 
        TAC 2455  2800  5 months LogNormal MCR 
      Weighted average cost of chemotherapy regimense     5 months LogNormal MCR 
        First three months on chemotherapy 1142  1099  3months LogNormal MCR 
        Next  419  432  2months LogNormal MCR 
    Cost of CSAEf 1263 978 – 1581 1,750 1376-2168 During 
chemotherapy LogNormal PC, HA and CL 
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Surveillanceg        
Low risk 79 47 – 111 74 62 – 85 12 months LogNormal PC 
      Intermediate risk 93 76 – 108 66 60 – 68 12 months LogNormal PC 
      High risk 106 78 – 133 77 69 – 82 12 months LogNormal PC 
After first year of diagnosis with ESBC        
Cost of endocrine therapyc        
Tamoxifen 12.4 11.6 – 13.2 12.4 11.6 – 13.2 48 months LogNormal DPIN 
      Aromatase inhibitors   156 120 – 193 48 months LogNormal DPIN 
      Aromatase +tamoxifen   72 62 – 81 48 months LogNormal DPIN 
Surveillanceg        
      Low risk 39 18 – 59 33 30 – 54 Life time LogNormal PC 
      Intermediate risk 35 32– 40 45 38 – 53 Life time LogNormal PC 
      High risk 102 65 – 126 39 32 – 45 Life time LogNormal PC 
Cost associated with LR (per month), $        
First year after LR        
Cost of Surgerya 3522 889 – 7280 2806 1068 – 3111 One time LogNormal PC, HA and CL 
Cost of Radiation therapyb 1098 878 – 1371 2120 1695 – 2651 One time LogNormal PC, HA and CL 
Cost of endocrine therapyc        
Tamoxifen 12.4 11.6 – 13.2 12.4 11.6 – 13.2 12 months LogNormal DPIN 
Aromatase Inhibitors   156 120 – 193 12 months LogNormal DPIN 
Sequential aromatase → tamoxifen   72 62 – 81 12 months LogNormal DPIN 
Cost Chemotherapyd 278 181 –  619 311 200 – 688 5 months LogNormal PC and CL 
Surveillance during first yearg 118 48 – 189 123 64 – 179 12 months LogNormal PC 
After first year of LR        
Cost of endocrine therapyc        
Tamoxifen 12.4 11.6 – 13.2 12.4 11.6 – 13.2 48 months LogNormal DPIN 
Aromatase Inhibitors   156 120 – 193 48 months LogNormal DPIN 
Sequential aromatase → tamoxifen   72 62 – 81 48 months LogNormal DPIN 
Surveillance after first year of LRg 98 33 – 162 78 18 – 139 Life time LogNormal PC 
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Cost associated with DR (per month), $        
First year after DR         
Hospitalization cost 841 138 – 253 1569 185– 3177 12 months LogNormal HA and CL 
Physicians cost  247 64 – 431 353 205 – 501 12 months LogNormal PC 
Drugs cost  19 5 – 34 83 29 – 134 12 months LogNormal DPIN 
After first year of DR        
Hospitalization cost 1293 146 – 3014 783 72 – 1618 Life time LogNormal HA and CL 
Physicians cost  204 86 – 322 183 62 – 337 Life time LogNormal PC 
Drugs cost  52 5 – 121 100 33 – 167 Life time LogNormal DPIN 
†  Beta distribution was used for other probability parameter estimates not included in this table.  
‡  The baseline utility for post-menopausal women aged 50 to 80 was 0.824 and for premenopausal women aged 20 to 49 was 0.89[155]. I derived utilities for each state 
by multiplying these baseline utility values by utility estimates for women with breast cancer [150, 153, 156-157], consistent with methodology as described by Fryback 
[154]. 
a Cost of breast cancer surgery: I used the Hospital Discharge Database and the Physician Claims Database to estimate the mean cost of hospitalization due to any breast 
cancer surgery (including one day hospitalization and using the ICD-9-CM procedure codes for a hospital abstract) within one year after diagnosis with ESBC and LR by 
menopausal status. 
b Cost of radiation therapy: Cost of radiation therapy included cost of radiation therapy–related physician claims in addition to administrative cost. I used the Physician 
Claims Database to estimate the mean cost of radiation therapy–related physician claims (using the tarrif code for a medical claim) within one year after diagnosis with 
ESBC and LR by menopausal status. Administrative costs were derived from the cost list for Manitoba health services. 
c Cost of endocrine therapy: I used the Drug Program Information Network to estimate the mean cost of tamoxifen and aromatase inhibitors by menopausal status (using 
the drug identification number for a drug claim) within the time periods, between diagnosis with ESBC and before any relapse, and diagnosis with LR and before any 
relapse.  
d Cost of chemotherapy: Nursing, overhead and administration costs were derived from the cost list for Manitoba health Services. I used the Physician Claims Database to 
estimate the mean cost of chemotherapy–related physician claims costs (using the tariff code for a medical claim) within one year after diagnosis with ESBC and LR by 
menopausal status. Chemotherapy regimens costs were estimated based on the market prices as of May 2010.  
e Weighted average cost of adjuvant chemotherapy regimens: I calculated the average cost of adjuvant chemotherapy regimens weighted to the observed proportion use of 
anthracyclines and taxanes by menopausal status. Weighted average cost of adjuvant chemotherapy regimens = proportion of women received non-anthracycline 
containing adjuvant chemotherapy × cost of CMF + proportion of women received anthracycline containing adjuvant chemotherapy (no added taxanes) × cost of AC +  
proportion of women received anthracyclines and taxanes containing adjuvant chemotherapy × cost of TAC. 
f Cost of CSAE: I used the Hospital Discharge Database and the Physician Claims Database to estimate the mean cost associated with hospitalizations due to any of the 
eight diagnoses which were considered CSAE among women who develop CSAE. I stratified the analysis by menopausal status. 
g Cost of surveillance: I defined the cost of breast cancer surveillance as the incremental cost of health care utilization (medical claims)after diagnosis with ESBC versus 
the time before diagnosis. I used the Physician Claims Database to collect medical claims for both post- and pre-menopausal women, within 3 years before and 7 years 
after diagnosis with ESBC. I estimated the mean cost of medical claims by menopausal status within 3 years before diagnosis in order to reflect the usual cost of health 
care utilization. I calculated the incremental mean cost of health care utilization by menopausal status during the period from diagnosis with ESBC and before any relapse 
(excluding cost of claims related to surgery, radiation therapy, chemotherapy and CSAE) stratified by the time following diagnoses (first year versus later). Similarly, I 
calculated the incremental mean cost of health care utilization by menopausal status after LR. 
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PSA= probabilistic sensitivity analysis; MCR= Manitoba Cancer Registry: PC= physician claims; HA= hospital abstracts; CL= cost list for Manitoba health services; 
DPIN=Drug Program Information Network records; ESBC= early stage breast cancer; LR, loco-regional recurrence; DR= distant recurrence; CMF= 6 cycles of 
cyclophosphamide, methotrexate, 5-fluorouracil; AC= 4 cycles of doxorubicin, cyclophosphamide; FAC=6 cycles of fluorouracil, doxorubicin, cyclophosphamide; 
TAC=6 cycles of docetaxel, doxorubicin, cyclophosphamide; CCP= current clinical practice. 
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Table 2. Proportion of patient population receiving adjuvant chemotherapy by diagnosis time period and menopausal status. 
 
 
Diagnosis time  
period 
No. of women diagnosed with ER+ or PR+ 
LN- ESBC No. of women received adjuvant chemotherapy (%) 
 
Pre-menopausal 
women 
Post-menopausal women Pre-menopausal 
women 
2000-2002 
vs. 
2003-2005 
ρ value† 
Post-menopausal 
women 
2000-2002 
vs. 
2003-2005 
ρ value† 
2000−2002 109 389 74 (69) 
.88 
73 (18.8) 
.7 2003−2005 106 506 71 (67) 90 (17.7) 
† Chi-square test. 
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3.3.3 Adjuvant Chemotherapy Regimens 
In Canada, from 2000-2002, two adjuvant chemotherapy regimens were recommended 
for women with ER+/ PR+ LN- ESBC: (1) 6 cycles of cyclophosphamide, methotrexate, 
5-fluorouracil (CMF) or (2) anthracycline-containing chemotherapy regimen such as 4 
cycles of doxorubicin (Adriamycin), cyclophosphamide (AC) or 6 cycles of 5-
fluorouracil, doxorubicin, cyclophosphamide (FAC) [117]. Four cycles of AC has been 
used preferentially as a component of chemotherapy regimens for the adjuvant treatment 
of ESBC [158]. Recently, chemotherapy regimens containing taxanes, such as 6 cycles of 
docetaxel, doxorubicin, cyclophosphamide (TAC), have been recommended for the LN- 
ESBC population [159]. 
The majority of adjuvant chemotherapy-treated women in our study cohort received 
anthracycline-containing adjuvant chemotherapy regimens (Table 2). Information on 
specific chemotherapy agents (e.g. CMF, AC, FAC, and TAC) was not available. I 
assumed patients who received non-anthracycline-containing adjuvant chemotherapy 
regimens received 6 cycles of CMF; that patients who received anthracycline-containing 
adjuvant chemotherapy regimens with no added taxanes received four cycles of AC; and 
that patients who received anthracycline and taxane-containing adjuvant chemotherapy 
regimens received 6 cycles of TAC. Thus, in the base case analysis, I used the weighted 
average cost of CMF, AC and TAC. 
Anthracycline-containing regimens may have a survival advantage compared to CMF 
regimens [160]. However, other studies showed anthracycline-containing regimens to 
have equivalent clinical outcomes compared to CMF regimens, particularly in women 
with favourable prognostic features (LN-, ER+/PR+) such as our study cohort [117, 161-
162]. Thus, in sensitivity analysis I considered each of the CMF, AC, FAC and TAC 
regimens separately as the standard adjuvant chemotherapy regimen for women with 
ER+/ PR+ LN- ESBC. 
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3.3.4 Adjuvant chemotherapy-related Serious Adverse 
Effects (CSAE) 
I defined CSAE as hospitalization for any of the following eight diagnoses (as defined by 
their ICD-9-CM diagnosis and procedure codes)occurring within one year of diagnosis 
with ESBC: 1) abnormal electrolytes or dehydration; 2) constitutional symptoms and 
nonspecific symptoms associated with therapy; 3) nausea, emesis, and diarrhea; 4) 
infection and fever; 5) malnutrition; 6) anemia and red cell transfusion; 7) neutropenia or 
thrombocytopenia; 8) deep venous thrombosis or pulmonary embolus[163-164]. These 
diagnoses were selected based on their association with chemotherapy in previous 
clinical trials[116]. I estimated the incremental rate of occurrence of CSAEs from the 
frequency of occurrence of these ICD-9 codes in hospital abstracts of adjuvant 
chemotherapy recipients versus non-recipients, stratified by menopausal status and 
adjusting for comorbidity indices using the method developed by Charlson et al 
excluding cancer diagnoses[165].  
3.3.5 Costs 
Treatment costs, including surgery, radiation therapy, chemotherapy, endocrine therapy, 
surveillance, and CSAE, are all publicly funded in Manitoba and are thus recorded in the 
administrative databases. For each patient in the studied cohort I gathered all treatment 
costs for the first 7 years following diagnosis with primary breast cancer (Table 1). I used 
this to estimate the cost per unit time in each Markov state. 
3.3.6 Utilities 
The baseline utility for post-menopausal women aged 50 to 80was 0.824 and for 
premenopausal women aged 20 to 49 was 0.89, based on representative values for the 
U.S. population [155]. I derived utilities for each health state by multiplying these 
baseline utility values by utility estimates for women with early-stage breast cancer [150, 
153-154, 156-157] (Table 1). I performed sensitivity analysis on the utility values after 
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chemotherapy to account for potential long term side effects of primary adjuvant 
chemotherapy [166]. 
3.4 Results 
Patient, tumor, treatment and event characteristics of the study cohort are summarized in 
Table 2. There were 109 pre-menopausal and 389 post-menopausal women diagnosed 
with ER+/ PR+ LN- ESBC in Manitoba from January 1, 2000 to December 31, 2002. The 
median age was 44 years (range 29-49 years) in pre-menopausal women and 62 years 
(range 50-88) in post-menopausal women. All pre- and post-menopausal women received 
surgery (mastectomy or breast-conserving surgery) for their primary breast cancer. 
Adjuvant therapy including radiation therapy, endocrine therapy (tamoxifen or aromatase 
inhibitors) and chemotherapy were administered in 63%, 81% and 69% of pre-
menopausal women, respectively, and in 52%, 79% and 19% of post-menopausal 
women, respectively. 
In pre-menopausal women, the RS-assay led to an increase of 0.05 QALY per person and 
decrease in cost of $50 per person resulting in a cost saving compared to CCP. In post-
menopausal women, the RS-assay led to an increase of 0.062 QALY per person and an 
increase in cost of $3,700 per person, resulting in an incremental cost effectiveness ratio 
(ICER) of $ 60,000 per QALY gained compared to CCP. 
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Table 3. Characteristics of 489 patients diagnosed during the time period of 2000 to 2002 with ER+ or PR+ 1-3 LN+ ESBC stratified 
by menopausal status and risk of recurrence using Canadian clinical practice guidelines. 
Characteristic 
Pre-menopausal women (n=109)  Post-menopausal women (n=389) ρ  
value† 
Low risk* 
(n=11) 
Intermedi
ate risk* 
(n=78) 
High risk* 
(n=20) 
Overall 
(n=109) 
 Low risk* 
(n=115) 
Intermediat
e risk* 
(n=196) 
High 
risk* 
(n=78) 
Overall 
(n=389)  
Age ( years)           
   Mean (range) 41.8  
(30 – 49) 
43.6  
(29 – 49) 
42.7  
(33-49) 
43  
(29-49) 
 63.4  
(50 -85) 
64  
(50 – 88) 
61.8  
(50 -86) 
63 
(50-88)  
<40 3 (27.3) 17 (21.8) 4 (20) 24 (22)  ― ― ― ―  
   40 – 49 8 (72.7) 61 (78.2) 16 (80) 85 (78)  ― ― ― ―  
   50 – 64 ― ― ― ―  64 (55.7) 111 (56.6) 53 (68) 228 (58.6)  
   ≥65 ― ― ― ―  51 (44.3) 85 (43.4) 25 (32) 161 (41.4)  
Primary tumor size – no. of women (%)            
<2 cm 11 (100) 51 (65.4) 7 (35) 69 (63.3)  115 (100) 117 (59.7) 17 (21.8) 260 (66.8) .78 
   2-5 cm  0 27 (34.6) 11 (55) 38 (34.9)  0 79 (40.3) 55 (70.5) 123 (31.7)  
>5 cm  0 0 2 (10) 2 (1.8)  0 0 6 (7.7) 6 (1.5)  
Receptor status – no. of women (%)           
   ER+ and PR- 0 11 (14.1) 7 (35) 18 (16.6)  25 (21.7) 54 (27.5) 30 (38.5) 109 (28) .016 
   ER- and PR+ 0 4 (5.2) 3 (15) 7 (6.4)  1 (0.9) 4 (2.1) 6 (7.7) 11 (2.8)  
   ER+ and PR+ 11 (100) 63 (80.7) 10 (50) 84 (77)  89 (77.4) 138 (70.4) 42 (53.8) 269 (69.2)  
Tumor grade – no. of women (%)           
   1  6 (54.5) 14 (18) 1 (5) 21 (19.3)  89 (77.4) 17 (8.7) 1(1.3) 107 (27.5) .37 
   2  0 50 (64.1) 5 (25) 55 (50.5)  0 160 (81.6) 21 (26.9) 181 (46.5)  
   3  0 5 (6.4) 14 (70) 19 (17.4)  0 6 (3) 53 (68) 59 (15.2)  
   Unknown  5 (45.5) 9 (11.5) 0 14 (12.8)  26 (22.6) 13 (6.7) 3 (3.8) 42 (10.8)  
Stage           
   I 11 (100) 55 (70.5) 7 (35) 73 (67)  115 (100) 145 (74) 21 (26.9) 281 (72.2) .56 
   IIA 0 23 (29.5) 11 (55) 34 (31.2)  0 51 (26) 51 (65.4) 102 (26.2)  
   IIB 0 0 2 (10) 2 (1.8)  0 0 6 (7.7) 6 (1.6)  
With Breast-surgery‡ – no. of women (%) 11 (100) 78 (100) 20 (100) 109 (100)  115 (100) 196 (100) 78 (100) 389(100)  
   Breast-conserving surgery 8 (72.7) 51 (65.4) 9 (45) 68 (62.4)  65 (56.5) 113 (57.7) 29 (37.2) 207 (53.4) .08 
   Mastectomy   3 (27.3) 27 (34.6) 11 (55) 41 (37.6)  50 (43.5) 83 (42.3) 49 (62.8) 182 (46.6)  
41 
 
With Radiotherapy‡ – no. of women (%) 7 (63.6) 51 (65.4) 11 (55) 69 (63.3)  62 (54) 109 (55.6) 30 (38.5) 201 (51.7) .03 
With Endocrine therapy‡ – no. of women (%) 5 (45.4) 65 (83.3) 18 (90) 88 (81)  91 (79.1) 165 (84.1) 53 (67.9) 309 (79.4) .76 
Tamoxifen 5 (100) 49 (75.4) 13 (72) 67 (76.1)  61 (67) 104 (63) 31 (58.5) 196 (63.4) .02 
   Aromatase inhibitors + tamoxifen 0 13 (20) 4 (22) 17 (19.3)  25 (27.5) 48 (29) 18 (34) 91 (29.5)  
   Aromatase inhibitors  0 1 (1.5) 0 1 (1.2)  5 (5.5) 10 (6) 3 (5.7) 18 (5.8)  
   Unknown type 0 2 (3) 1 (5.5) 3 (3.4)  0 3 (2) 1 (1.8) 4 (1.3)  
With adjuvant Chemotherapy‡ – no. of women (%) 3 (27.3) 51 (65.4) 20 (100) 74 (69)  3 (2.6) 28 (14.3) 42 (53.8) 73 (18.8) < .0001 
   No anthracyclines 0 17 (33.3) 5 (25) 22 (35.6)  1  9 (32.1) 16 (38.1) 26 (29.7) .88 
Anthracyclines, no taxanes 3 (100) 29 (56.9) 12 (60) 44 (54.8)  1 16 (57.1) 23 (54.8) 40 (59.5)  
Anthracyclines and taxanes 0 2 (3.9) 2 (10) 4 (4.1)  0 0 3 (7.1) 3 (5.4)  
Unknown type  0 3 (5.9) 1 (5) 4 (5.5)  1 3 (10.8) 0 4 (5.4)  
Loco-regional recurrence event – no. of women (%) 0 4 (5.1) 2 (10) 7 (6.4)  1 (.86) 2 (1) 10 (12.8) 13 (3.3) .14 
Distant recurrence event – no. of women (%) 0 3 (3.8) 3 (15) 6 (5.5)  2 (1.7) 10 (5.1) 14 (17.9) 26 (6.7) .65 
Deaths – no. of women (%) 0 3 (3.8) 3 (15) 6 (5.5)  10 (8.6) 31 (15.8) 22 (28.2) 63 (16.2) .004 
Charlson co-morbidity score mean (SE, range)¶ 0 0.10 0.05 0.08  (0.03, 0–2) 
 0.11 0.20 0.19 0.18  (0.03, 0–6) .028 
Charlson co-morbidity score – no. of women (%)¶ 
    
 
     
   0  11 (100) 71 (91) 19 (95) 101(92.6)  104 (90.4) 171 (87.3) 69 (88.4) 344 (88.4) .86 
   1  0 6 (7.7) 1 (5) 7 (6.4)  9 (7.8) 18 (9.2) 6 (7.7) 33 (8.4)  
   2  0 1 (1.3) 0 1 (1)  2 (1.8) 3 (1.5) 1 (1.3) 6 (1.5)  
   3  0 0 0 0  0 2 (1) 1 (1.3) 3 (.8)  
   4  0 0 0 0  0 0  1 (1.3) 1 (.3)  
   5  0 0 0 0  0 1 (.5) 0 1 (.3)  
   6 0 0 0 0  0 1 (.5) 0 1 (.3)  
*Categorization of a patient’s risk for recurrence as low, intermediate, or high was according to the Canadian clinical practice guidelines [117]. Low risk: Post-menopausal women with primary tumor size < 
2cm and tumor grade = 1; pre-menopausal women with primary tumor size < 1cim and tumor grade =1. High risk: All women with tumor size >3cm, or women with tumor size ≥ 1cm and ≤ 3cm with tumor 
grade = 3. Intermediate risk: Post-menopausal women with tumor size < 2cm and tumor grade > 1, or tumor size ≥ 2cm and < 3cm and tumor grade = 1 or 2; premenopausal women with tumor size < 1cm and 
tumor grade >, or tumor size ≥ 1cm and < 3cm and tumor grade=1 or 2. Given the significant correlation between tumor size, lymphatic and vascular invasion [144], and tumor grade[167],  lymphatic and 
vascular invasion was not used in categorizing patients’ risk because the Manitoba cancer registry does not collect this information and 52 patients ‘risk for recurrence was categorized on the basis of tumor 
size only because their tumors size < 3cm with undetermined tumors grade. 
†The p-value was calculated for overall pre- vs. overall post-menopausal women. Fisher’s exact and chi-square tests were used for binary and categorical variables respectively. Distributions of continuous 
variables were summarized by their means and standard errors and compared using t-tests. 
‡Women were defined as having received any of these treatments for their primary breast cancer if the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) procedure 
code or the Canadian Classification of Health Interventions (CCI) procedure code of any of these treatments was found before any recurrence, second primary cancer or death within one year of diagnosis with 
ESBC. 
¶ Co-morbid diagnoses were considered present if they were found during one year before and 6 months after the diagnosis with primary breast cancer. 
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3.5 Sensitivity Analysis 
In the base case I compared the RS assay versus CCP when weighted average cost of 
CMF, AC and TAC was used. I considered each of CMF, AC, FAC and TAC regimens 
separately as the standard adjuvant chemotherapy regimen for women with ER+/ PR+ 
LN- ESBC in sensitivity analysis. In premenopausal women, the RS-assay stayed cost 
saving with each of CMF, AC, FAC and TAC regimens. In post-menopausal women, the 
RS-assay had an ICER of $59,800 per QALY gained with CMF, $58,200 per QALY 
gained with AC, $65,000 per QALY gained with FAC and $83,100 per QALY gained 
with TAC. The utility during chemotherapy and the rates and costs of CSAE did not 
substantially influence the results with any regimen. 
I performed threshold analyses on the proportion of chemotherapy-treated women 
classified as being in the intermediate risk group by the RS-assay, on the risk of relapse 
in the RS-assay model and other parameters found to influence our base case analyses 
(Tables 4 and 5). Among pre-menopausal women, the RS-assay generated negative 
incremental cost and effect (the RS-assay led to decrease in cost and effect) and when 
fewer than 43% of women in the RS-assay intermediate risk group received adjuvant 
chemotherapy. Among postmenopausal women, the RS-assay was dominated by CCP 
when fewer than 31% of women in the RS-assay intermediate risk group received 
adjuvant chemotherapy. When the absolute risk of relapse in the RS-assay model 
increased by approximately 2% in either pre- or post-menopausal women, the RS-assay 
would be dominated by CCP or associated with negative incremental cost and effect. 
I also performed a probabilistic sensitivity analysis (Figure 2) comparing the RS-assay 
versus CCP. I simultaneously varied all parameters (probabilities, utilities and costs) 
using appropriate distributions (Table 1). In pre-menopausal women, using a willingneess 
to pay threshold of $100,000 per QALY gained, I found that the RS-assay was the 
prefered strategy in 54% of simulations (Figure 2 a and b). In post-menopausal women, I 
found that the RS-assay was the prefered strategy in 62% of simulations (Figures 2 c and 
d).
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Table 4. Summary of important one-and two way sensitivity analysesa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Interpretation of the incremental impact of the RS-assay compared to CCP 
 
 Variable (range tested) 
Negative 
cost and 
effect 
Cost saving 
ICER  in the 
range 
0 to 20,000 
$/QALY 
gained 
ICER in the range  
20,000 to 100,000 
$/QALY 
gained 
ICER  in the 
range 
>100,000 
$/QALY 
gained 
Dominated 
Chemotherapy treated women in intermediate 
risk group by the RS-assay (0% to 100%) 0% to 42% 43% to 63% 64% to 100%    
Change in absolute risk of relapsebin the RS-
assay model 
(-10% to +10%) 
> +1.8% ≤ +1.8%     
Change in utility of 
recurrencec 
(-10% to +10%) 
 
Lower limit cost of 
recurrencec 
  ≤ +2.2% +2.3% to +3.4% +3.5% to +4% ≥ +4% 
Baseline cost of 
recurrencec 
> +3% ≤ +3%     
Upper limit cost of 
recurrencec 
> +3% ≤ +3%     
Change in utility following adjuvant 
chemotherapy (-10% to +10%) > +1% ≤ +1%     
CMF= 6 cycles of cyclophosphamide, methotrexate, 5-fluorouracil; AC= 4 cycles of doxorubicin, cyclophosphamide; CCP= current clinical practice. 
aValues in the table show how the incremental impact of the RS-assay compared to CCP changes, over 6 significant ranges, depending on the values of certain key 
parameters. For example, if between 43-63% of women identified as intermediate risk by the RS-assay were to receive chemotherapy, then the RS-assay would be cost 
saving relative to CCP; if this proportion is 64% or greater, then the RS-assay has an ICER between 0 and $20,000 / QALY gained. 
bRelapse includes loco-regional recurrence, distant recurrence and death due to any cause. 
cRecurrence includes loco-regional and distant recurrences. 
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Table 5. Summary of important one-and two way sensitivity analysesa. 
 
 
 
 
 
 
 
 
 
 
Interpretation of the incremental impact of the RS-assay compared to CCP 
 
Variable (range tested) 
Negative 
cost and 
effect 
Cost 
savings 
ICER  in the 
range 
0 to 20,000 
$/QALY 
gained 
ICER  in the range 
20,000 to 100,000 
$/QALY 
gained 
ICER  in the 
range 
> 100,000 
$/QALY 
gained 
Dominated 
Chemotherapy treated women in 
intermediate risk group by the RS-assay 
(0% to 100%) 
  86% to 100% 42% to  85% 32% to  41% 0% to 31% 
Change in absolute risk of  relapseb  in 
the RS-assay model 
(-10% to +10%) 
  < -3% -3 % to  +0.9% +1% to +2% > +2% 
Change in utility of 
recurrencec 
(-10% to +10%) 
 
Lower limit 
cost of 
recurrencec 
   < +9% ≥ +9%  
Baseline cost 
of recurrencec    -10% to +10%   
Upper limit 
cost of 
recurrencec 
   -10% to +10%   
Change in utility following adjuvant 
chemotherapy (-10% to +10%)   > 4.5% -0.8% to +4.5% -2.4% to -0.9% ≤ -2.5% 
CMF= 6 cycles of cyclophosphamide, methotrexate, 5-fluorouracil; AC= 4 cycles of doxorubicin, cyclophosphamide; CCP= current clinical practice. 
a
 Values  in the table show how the incremental impact of the RS-assay compared to CCP changes, over 6 significant ranges, depending on the values of certain 
key parameters. For example, if between 43-63% of women identified as intermediate risk by the RS-assay were to receive chemotherapy, then the RS-assay 
would be cost saving relative to CCP; if this proportion is 64% or greater, then the RS-assay has an ICER between 0 and $20,000 / QALY gained. 
b
 Relapse includes loco-regional recurrence, distant recurrence and death due to any cause. 
c
 Recurrence includes loco-regional and distant recurrences. 
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Figure 2. Incremental cost-effectiveness scatterplot and acceptability curve of RS-assay-guided therapy versus 
CCP-guided therapy for pre- and post-menopausal women. Sampling distributions and summary estimates of 
cost, efficacy, and variance were based on 1000 replicates. 
Pre-menopausal Women 
a b 
Incremental Cost Effectiveness Scatterplot of RS-
assay versus CCP 
Cost Effectiveness Acceptability Curve of RS-
assay versus CCP 
  
Post-menopausal Women 
c d 
Incremental Cost Effectiveness Scatterplot of RS-
assay versus CCP 
Cost Effectiveness Acceptability Curve of RS-
assay versus CCP 
 
 
          CCP 
         RS-assay 
CCP= current clinical practice. 
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3.6 Discussion 
I developed a decision-analytic model to evaluate the cost effectiveness of the RS-assay 
versus CCP in ER+/ PR+ LN- ESBC. In the base case I estimated that the RS-assay 
generated cost savings in pre-menopausal women and has an ICER of $60,000 per QALY 
gained in post-menopausal women. 
In Canada, an ICER threshold of $100,000 per QALY gained has been suggested as 
representing “weak evidence for adoption and appropriate utilization” [62, 72], although 
there is no evidence that any Canadian decision-making body has formally implemented 
this threshold [168]. The ICERs of the RS-assay in post-menopausal women were within 
ranges of a number of cancer treatments that have recently been approved in Canada. For 
instance, sorafenib has an estimated ICER of $75,821 per life year gained for the 
treatment of hepatocellular carcinoma and has been approved for funding in Ontario 
through the Exceptional Access Program [169]. Sunitinib has been funded in all 
Canadian provinces for first-line treatment of metastatic renal-cell carcinoma with an 
ICER of $144,000 per QALY gained [170]. 
Previous cost-effectiveness analyses of the RS-assay in ER+/ PR+ LN- ESBC population 
have several limitations and may not be applicable in the Canadian context. One study 
[127] did not incorporate results from NSABP B20 [11], which established the 
relationship between the RS-assay and the benefit from using chemotherapy. Another two 
studies [128-129] included results from NSABP B20 [128]; however, the treatment 
strategies that they compared (tamoxifen alone for everyone and tamoxifen and 
chemotherapy for everyone) do not reflect observed clinical practice in Canada (Table 2). 
Other studies from Israel [131] and Japan [130] did not incorporate all early stage breast 
cancer complications such as local or regional recurrence.  Three recent studies [132-134] 
were conducted from the Canadian health care payer’s perspective; however, the first 
analysis [132] did not address all the limitations mentioned above, and modeling the 
current experience of ER+/ PR+ LN- ESBC population with regard to survival in the 
three analyses [132-134] was not based on Canadian data and real world clinical practice. 
In all studies there was no differentiation in adjuvant chemotherapy practice between pre- 
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and post-menopausal women as recommended by Canadian guidelines [117], whereas I 
observed differences in clinical practice for these two groups (Table 2). 
Adjuvant chemotherapy is a widely recommended treatment in ER+/ PR+ LN- ESBC 
[124]. Thus, some have suggested that large cost savings can be expected by avoiding 
chemotherapy treatment in 25% to 35% of patients based on the results of the RS-assay 
[124]. Our analysis suggests that cost savings may be possible in pre-menopausal women, 
due the wide use of chemotherapy in this group, but would likely not occur with post-
menopausal women with ER+/ PR+ LN- ESBC. According to our analysis, the RS-assay 
results may increase chemotherapy treatment in aproximetly15% of post-menopausal 
women with ER+/ PR+ LN- ESBC and would generate favorable QALYs gained and 
increase costs over CCP in this patient population. This scenario is likely due to both the 
ability of the RS-assay to better distinguish patients who likely benefit from 
chemotherapy compared to CCP and the possibility that many of post-menopausal 
women in CCP are reluctant to undergo chemotherapy and would be persuaded of its 
importance because of the test results [171]. 
In sensitivity analysis I addressed the economic impact of uncertainty in clinical 
guidelines for intermediate-range RS-assay values(18-30) [172]. Our analysis 
demonstrated that the ability of the RS-assay to guide treatment decisions in the 
intermediate risk group likely would be important in determining whether the RS-assay 
will be a cost-effective use of resources. If fewer than 43% of pre-menopausal and 31% 
of post-menopausal women identified as intermediate risk by the RS-assay received 
adjuvant chemotherapy, then the RS-assay had negative health effects compared to CCP. 
An ongoing prospective clinical trial will further assess the predictive value of the assay 
in women in the intermediate risk group and will be helpful in verifying our results [25]. 
However, findings from this trial will not be available for 5 to 10 years whereas an 
adoption decision will need to be made prior to having the results of this trial. 
Our analysis has several limitations. First, there are limits to what can be ascertained 
through administrative data. Although the Manitoba Cancer Registry is a highly accurate 
source of information about breast cancer [137], errors in coding can result in incorrect or 
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unrecorded procedures. However, wherever possible I cross validated across databases. 
For instance, information on breast cancer treatments including surgery, radiation 
therapy, endocrine therapy and chemotherapy can be found in both the Manitoba Cancer 
Registry and the administrative databases held by Manitoba Health and Healthy Living. 
Second, validation data for the 21-gene assay was based on retrospective analyses of the 
NSABP chemotherapy-tamoxifen trials (B-14 and B-20) conducted in the United States 
[11, 121]. Thus, survival outcomes by the RS-assay may not reflect the experience of the 
ER+/PR+ LN- ESBC identified in Manitoba due to possible differences in patient and 
tumor characteristics and treatments. Results from future prospective analyses of the 
assay in real-world clinical practice and in Canadian settings can be used to update our 
model and verify our results. Third, there is still uncertainty as to whether chemotherapy 
is necessary for women who fall in the intermediate risk group by the RS-assay [25]. 
Fourth, newer third generation anthracycline-taxane regimens have different costs and 
slightly better efficacy so analysis with such data would be more applicable to the current 
practice landscape. In addition, our analysis did not account for growing data on long 
term side effects of primary adjuvant chemotherapy such as cardiomyopathy, neuropathy, 
and leukemia [166]. Finally, although several studies have found that clinical practice 
patterns and therapies employed in the selected time periods in Manitoba reflect practice 
in other jurisdictions in Canada [173-175], differences in clinical practice for women 
with ER+/PR+ LN- ESBC and its associated costs across Canadian provinces may still 
exist. 
3.7 Conclusion 
I compared the RS-assay versus current clinical practice in ER+/ PR+ LN- ESBC for 
both pre- and post-menopausal women. I found that it is likely to be cost-saving for pre-
menopausal women and to have an ICER that is within ranges of a number of cancer 
treatments recently approved for funding in Canada for post-menopausal women. 
Validation of the assay in real-world clinical practice is warranted to verify the 
retrospective analyses of this assay in clinical trials and ensure its cost-effectiveness for 
routine use in this population.  
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Chapter 4  
4 Cost-effectiveness of a 21-gene recurrence score 
assay versus Canadian clinical practice in post-
menopausal women with early-stage estrogen or 
progesterone-receptor-positive, axillary lymph-node 
positive breast cancer 
4.1 Abstract 
A 21-gene recurrence score (RS) assay provides a method of guiding treatment decisions 
in women with early-stage breast cancer (ESBC). I investigated the cost-effectiveness of 
using the RS-assay versus current clinical practice (CCP) in post-menopausal women 
with estrogen- or progesterone-receptor-positive (ER+ or PR+), one to three positive 
axillary lymph-node (1-3 LN+), ESBC from the perspective of the Canadian public 
healthcare system. I developed a decision analytic model to project the lifetime clinical 
and economic consequences of ESBC. I assumed that the RS-assay would classify 
patients among risk levels (low, intermediate and high) and corresponding adjuvant 
treatment regimens. The model was parameterized using 7 year follow up data from the 
Manitoba Cancer Registry, cost data from Manitoba Health administrative databases and 
secondary sources. Costs are presented in 2012 Canadian dollars, and future costs and 
benefits were discounted at 5%. In the base case, the RS-assay compared to CCP led to 
an increase of 0.08 QALY and an increase in cost of $36.2 CAD per person, resulting in 
an incremental cost effectiveness ratio (ICER) of $464/QALY gained. The ICER was 
most sensitive to the proportion of women classified to intermediate risk by the RS-assay 
who received adjuvant chemotherapy, and absolute risk of relapse among patients 
receiving RS-assay. The RS-assay is likely to be cost effective in the Canadian healthcare 
system. Field evaluations of the assay in this patient population will help reduce 
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uncertainty in clinical guidelines for intermediate-range RS-assay values and specific 
disease outcomes by RS-assay which are important drivers of ICER. 
4.2 Introduction 
Postmenopausal women with early stage estrogen or progesterone-receptor-positive, 
axillary lymph-node positive breast cancer (ER+ or PR+ LN+ ESBC) are routinely 
treated with chemotherapy in addition to endocrine therapy [176]. Recent data in Canada 
and other jurisdictions have shown that these women, particularly those with favorable 
histopathologic features (one to three positive axillary lymph nodes (1-3 LN+)), do not 
benefit equally from chemotherapy [22, 177]. Further analyses have suggested that some 
of these women may not gain benefit from adding chemotherapy to endocrine therapy 
[177], [20]. These findings have highlighted the need for accurate prognostic tools to 
identify women with ER+ or PR+ 1-3 LN+ ESBC who could be spared chemotherapy. 
A 21-gene recurrence score assay (Oncotype DX) has been developed that provides a 
“tumor signature” reflecting tumor biology and risk of relapse [11, 18-20]. This assay 
uses a proprietary algorithm to combine tumor expressions of 21 genes into a single score 
called the recurrence score (RS) which ranges from 1 to 100 [18]. Women with a low RS 
(< 18) may need adjuvant endocrine therapy only, while those with a high RS (≥ 31) may 
require the addition of chemotherapy to endocrine therapy [11, 19]. Women with an 
intermediate risk (18 – 30) do not appear to obtain a large benefit from chemotherapy.  
However, the uncertainty in the estimate cannot exclude a clinically important benefit 
[11, 20, 25]. 
The prognostic value of the assay has been well documented for women with early-stage 
estrogen or progesterone-receptor-positive, axillary lymph-node negative breast cancer 
(ER+ or PR+ LN- ESBC) [11, 18-19]. There is increasing evidence that the recently 
developed RS-assay can also identify women with ER+ or PR+ LN+ breast cancer 
considered for adjuvant chemotherapy who will not benefit from this treatment [20, 120, 
178-179]. The most comprehensive analysis of the RS-assay in women with ER+ or PR+ 
LN+ breast cancer was provided by a retrospective analysis of the phase III Southwest 
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Oncology Group (SWOG)-8814, INT-0100 trial. The RS-assay was found to predict 
disease free survival and overall survival in tamoxifen-treated post-menopausal women 
with LN+, providing the first evidence of prognostic utility of the assay in a LN+ 
population receiving tamoxifen alone. In this study, it was shown that a low recurrence 
score by the assay may define a group of post-menopausal women with LN+ who do not 
appear to benefit from adjuvant chemotherapy [20]. A retrospective analysis of the 
“Arimidex, Tamoxifen, Alone or in Combination” trial (ATAC) validated the prognostic 
ability of the RS-assay in post-menopausal women with LN+ breast cancer treated with 
endocrine therapy (anastrozole or tamoxifen). Specifically, the study defined a group of 
ER+, 1-3 LN+ breast cancer patients with a low recurrence score who had less than 10 % 
risk of distant recurrences [179]. Consistent results by both retrospective analyses [20, 
179] provided “Level I” data according to the revised Levels of Evidence (LOE) scale 
proposed by Simon el al [180] to determine the clinical utility of a tumor marker. Other 
studies have also shown similar prognostic utility of the RS-assay in LN+ disease setting 
[120, 178]. 
There are several economic evaluations suggesting that the RS-assay might be cost 
effective in the ER+ or PR+ LN- ESBC population in Canada [132-134, 181], and other 
countries [127-131]. However, findings in the LN- disease setting cannot be extrapolated 
to LN+ disease setting due to differences in both clinical and economic outcomes. Three 
economic analyses have examined the cost effectiveness of the RS-assay in both LN-and 
LN+ settings [130, 133-134, 182]. These analyses suggested that the assay is cost-
effective for LN+ women in Canada[133], USA [182], and Japan [130]. However, none 
of these analyses focused on the low risk subset of LN+ disease setting (1-3 LN+) for 
whom the RS-assay is likely to be used in real world clinical practice, and suffered from 
other limitations as indicated elsewhere [181]. Additionally, findings from studies in 
USA and Japan cannot be extrapolated to the Canadian context because of possible 
variations in clinical practice and different approaches to pricing and reimbursement. 
I sought to investigate the cost effectiveness of the RS-assay compared to current clinical 
practice (CCP) of adjuvant chemotherapy in women with ER+ or PR+ 1-3 LN+ ESBC 
from the perspective of the Canadian healthcare system. 
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4.3 Methods 
4.3.1 Overview of Model-Structure 
I developed a decision analytic model (Figure 3) to estimate the life time health and 
economic consequences of different adjuvant treatment-guiding strategies for 
postmenopausal women diagnosed with ER+ or PR+ 1-3 LN+ ESBC. The decision node 
(Figure 3 a) of this model is a decision whether to use the RS-assay or the CCP strategy. 
For the RS-assay-based strategy, a patient’s risk classification (low, intermediate and 
high) was determined and followed by treatments decision (endocrine therapy plus 
chemotherapy versus endocrine therapy alone) according to the RS-assay. For the CCP 
based-strategy, all women are considered high risk and candidates for adjuvant 
chemotherapy [176]. CCP classifies patients to different treatment regimens after taking 
into consideration potential comorbidities. In either strategy, patients treated with 
endocrine therapy alone followed Markov model “E” (Figure 3b) and those treated with 
chemotherapy plus endocrine followed Markov model “C” (Figure 3c). Model “C” 
differs from model “E” in that it has an additional health state to account for possible 
chemotherapy-related serious adverse effects (CSAE) during chemotherapy. 
Model “E” simulated monthly transitions among the following five distinct health 
states: (1) remission; (2) loco-regional recurrence (LR); (3) distant recurrence (DR); (4) 
second primary breast cancer (SPBC); (5) death. Model “C” simulated monthly 
transitions among the following six distinct health states: (1) remission with no CSAE; 
(2) remission with CSAE; (3) LR; (4) DR; (5) SPBC; (6) death. 
The analysis was conducted from the Canadian health care payer’s perspective. I 
used TreeAge Software to produce and evaluate the decision analytic model, using a half 
cycle correction [136]. A discount rate of 5% per annum was applied to costs and quality 
adjusted life years (QALYs) following recommendations by the Canadian Agency for 
Drugs and Technologies in Health [111]. Parameter values are summarized in Table 1. 
Collection and analysis of registry and administrative data used for this study was 
approved by the University of Manitoba’s Health Research Ethics Board. 
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Figure 3. Decision model for early stage breast cancer. 
a  RS-assay versus CCP-guided therapy. 
 
b  Schematic representation of the Markov model structure “E”. 
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c  Schematic representation of the Markov model structure “C”. 
 
Patients entering Markov model “E” start the model and remain in the remission state unless they relapse (LR, DR, SPBC 
or Death). Patients entering Markov model “C” start the model in the remission state with no CSAE. Within the first cycle 
patients may develop CSAE. These patients will make a transition to the remission state with CSAE. During the first cycle, 
patients also may transition to DR, LR, SPBC and Dead states. After the first cycle, patients may remain in the two 
remission states unless they relapse in to LR, DR, SPBC or Dead. In both Markov models, patients who developed LR, 
remain in the LR state or make transition to DR or Dead states. Patients who developed DR remain in the DR state or make 
transition to Dead state. Patients who developed SPBC remain in the SPBC state or make transition to LR, DR or Dead 
states. The cycle length was 1 month. Abbreviations: CCP= Canadian clinical practice; LR= loco-regional recurrence; 
DR= distant recurrence; SPBC= second primary breast cancer; CSAE= chemotherapy-related serious adverse effects; RS= 
recurrence score. 
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4.3.2 Identification of a Study Cohort 
The Manitoba Cancer Registry (MCR) and Manitoba administrative databases held by 
Manitoba Health, including the Hospital Discharge Database, Physician Claims Database 
and the Drug Program Information Network (DPIN), served as the main data source for 
this analysis. I used the MCR to identify all post-menopausal women (defined as age ≥50 
years) diagnosed with ER+ or PR+ 1-3 LN+ ESBC (stage II/III) during the period 
January 1, 2000 − December 31, 2002. Seven-year follow-up information from the time 
of diagnosis was available for each patient. This included breast cancer complications 
(LR, DR and SPBC) and treatments (surgery, radiation therapy, endocrine therapy and 
chemotherapy). I linked the study population identified using the MCR with 
administrative data held by Manitoba Health including the Hospital Discharge Database, 
the Physician Claims Database and the Drug Program Information Network. 
Identification of our study cohort from MCR and linking with Manitoba administrative 
databases are described in detail elsewhere [177]. 
4.3.3 Risk Distribution and Transition Probabilities 
For the CCP model, women were classified as belonging to two treatment groups based 
on observed adjuvant chemotherapy administration status (Table 6). I conducted survival 
analyses within each group, using 7 years of follow up data from the Manitoba Cancer 
Registry and Kaplan-Meier estimates, and used this information to estimate all transition 
probabilities in the CCP Markov models. 
For the RS-assay model, I used retrospective analysis of the phase III SWOG-8814, INT-
0100 trial to calculate the risk distribution and monthly transition probabilities to LR, 
DR, SPBC and Death over 10 years within each risk level (Table 6) [20]. I obtained 
Kaplan Meier (KM) survival curves for DFS and death events stratified by risk level from 
SWOG investigators. These survival curves were restricted to women with 1-3 LN+ for 
the purpose of our patient population of interest. DFS was defined as survival free from 
recurrence (LR or DR), SPBC, and death from any cause. I estimated the distribution of 
DFS events across LR, DR, SPBC and death categories based on a corresponding 
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distribution of DFS events across these categories derived from our studied ER+/ PR+ 1-
3 LN+ ESBC cohort. 
Ongoing research is yet to clarify what the best adjuvant treatment approach is for 
women with intermediate-range RS-assay values. For LN+ patients, the only available 
data were provided recently by a survey of physician practice showing an overall 
reduction in recommendation for chemotherapy in LN+ patients following the RS-assay 
[183]. However, the study did not provide the actual usage of chemotherapy in 
intermediate risk women with LN+ disease. In the base case I assumed that 50% of 
women in the intermediate risk group would receive adjuvant chemotherapy as suggested 
elsewhere [181]. I varied this assumption in sensitivity analysis. 
Outcomes after first relapse (LR, DR, SPBC and Death) may not be affected by the 
primary adjuvant therapy received [150]. Thus, only the probabilities of first relapse 
differed between the CCP and RS-assay based strategy. I assumed the observed average 
monthly transition probability from remission to first relapse during the last observed 
year of follow up in the studied population and the SWOG-8814, INT-0100 trial to be 
constant over the extrapolated time period. I used the age-adjusted female-specific life 
tables for Manitoba to adjust the probabilities from remission to death in order to account 
for the incremental mortality risk over the extrapolated time [151]. 
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Table 6. Base case parameter estimates and sources. 
 
Variables  
Base 
case 
value 
Duration 
Range tested 
in sensitivity 
analyses€ 
Distribution 
used in 
PSA† 
Data Source 
Risk classification when using CCP (%)      
High risk 100     
Risk classification when using RS- assay (%)      
High risk 32.2  27.6 – 37.1 Dirichlet [20] 
Intermediate risk                                                      28.1  23.7 – 32.9 Dirichlet [20] 
Low risk 39.8  34.9 – 44.9 Dirichlet [20] 
Chemotherapy administration by risk group (%)      
CCP – High risk 64  56.3 – 70.1 Beta MCR and PC 
RS-Assay – High risk 100  90 – 100 Beta [20] 
RS-Assay – Medium Risk 50  0 – 100 Beta [131, 148-149, 152] 
RS-Assay – Low Risk 0  0 – 10 Beta [20] 
CSAE (%) 6  0 – 14.6 Beta MCR and HA 
Health-State Utilities‡ 
 
     
Remission state      
     Remission on chemotherapy regimen with 
     minor or no toxicityβ 0.783 6 months -20% Beta [153-155] 
     Remission on chemotherapy regimen with 
     major toxicityβ 0.577 6 months -20% Beta [153-155] 
     Remission after chemotherapy regimen 0.808 Lifetime -20% Beta [155-156] 
     Remission on hormonal therapy 0.816 60 months -10% – +10% Beta [153-155] 
     Remission after hormonal therapy 0.824 Lifetime -10% – +10% Beta [153-155] 
LR/SPBC, under treatment 0.577 12 month -10% – +10% Beta [150, 153-155, 184] 
LR/SPBC, after treatment 0.700 Lifetime -10% – +10% Beta [150, 153-155, 184] 
Distant recurrence 0.412 Lifetime -10% – +10% Beta [150, 153-155] 
Death state 0     
Cost associated with remission (per month), $      
First year after diagnosis with ESBC      
     Cost of surgerya 3529 One time 3187 – 3871 LogNormal PC, HA and CL 
     Cost of radiation therapyb 3276 One time 2628 – 4086 LogNormal PC and CL 
     Cost of endocrine therapyc      
Tamoxifen 12.4 12 months 11.6 – 13.2 LogNormal DPIN 
          Aromatase Inhibitors 156 12 months 120 – 193 LogNormal DPIN 
          Sequential aromatase→ tamoxifen 72 12 months 62 – 81 LogNormal DPIN 
     Cost of chemotherapyd      
          Nursing, overhead and administration costs  317.62 During 
chemotherapy  LogNormal CL 
          Related physician costs  27 During 
chemotherapy 24 – 30 LogNormal PC 
          Chemotherapy regimen options      
               CMF 823 5 months  LogNormal MCR 
               CA 1151 
 
3 months 
 
 LogNormal MCR 
               TAC 2800 5 months  LogNormal MCR 
               Weighted average cost of chemotherapy regimense      
                    First three months on chemotherapy 1099 3months  LogNormal MCR 
                    Next  432 2months  LogNormal MCR 
     Cost of CSAE f   1,750 During 
chemotherapy 1376 – 2168 LogNormal PC, HA and CL 
     Surveillance g      
          Endocrine alone treated-patient 56 12 months 54 – 62 LogNormal PC 
          Chemo + endocrine treated-patient   99 12 months 96 – 103 LogNormal PC 
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After first year of diagnosis with ESBC      
     Cost of endocrine therapyc      
Tamoxifen 12.4 48 months 11.6 – 13.2 LogNormal DPIN 
          Aromatase Inhibitors 156 48 months 120 – 193 LogNormal DPIN 
          Sequential aromatase→ tamoxifen 72 48 months 62 – 81 LogNormal DPIN 
Surveillancef      
          Endocrine alone treated-patient 34 Lifetime 30– 39 LogNormal PC 
          Chemo + endocrine treated-patient 44 Lifetime 39 –  51 LogNormal PC 
Cost associated with LR (per month), $      
First year after LR      
Surgerya 1768 One time 1092 –3313 LogNormal PC, HA and CL 
     Radiation therapyb 1725 One time 1353 – 2181 LogNormal PC, HA and CL 
     Cost of  endocrine therapyc      
Tamoxifen 12.4 12 months 11.6 – 13.2 LogNormal DPIN 
          Aromatase Inhibitors 156 12 months 120 – 193 LogNormal DPIN 
          Sequential aromatase→ tamoxifen 72 12 months 62 – 81 LogNormal DPIN 
Chemotherapyd 438 5 months 278 – 970 LogNormal PC and CL 
     Surveillance during first yearg 110 12 months 41 – 261 LogNormal PC 
After first year of LR      
     Cost of  endocrine therapyc      
Tamoxifen 12.4 48 months 11.6 – 13.2 LogNormal DPIN 
          Aromatase Inhibitors 156 48 months 120 – 193 LogNormal DPIN 
          Sequential aromatase→ tamoxifen 72 48 months 62 – 81 LogNormal DPIN 
     Surveillance after first year of LRg 40 Lifetime 30 – 87 LogNormal PC 
Cost associated with SPBC (per month), $      
First year after SP      
Surgerya 1494 One time 923 – 2800 LogNormal PC, HA and CL 
     Radiation therapyb 1092 One time 286 – 510 LogNormal PC, HA and CL 
     Endocrine therapy (options)c      
Tamoxifen 12.4 12 months 11.6 – 13.2 LogNormal DPIN 
          Aromatase Inhibitors 156 12 months 120 – 193 LogNormal DPIN 
          Sequential aromatase→ tamoxifen 72 12 months 62 – 81 LogNormal DPIN 
Chemotherapyd 553 5 months 353 – 1235 LogNormal PC and CL 
     Surveillance during first yearg 124 12 months 60 – 278 LogNormal PC 
After first year of SPBC      
     Cost of  endocrine therapyc      
Tamoxifen 12.4 48 months 11.6 – 13.2 LogNormal DPIN 
          Aromatase Inhibitors 156 48 months 120 – 193 LogNormal DPIN 
          Sequential aromatase→ tamoxifen 72 48 months 62 – 81 LogNormal DPIN 
     Surveillance after first year from SPBCg 55 Lifetime 35 – 95 LogNormal PC 
Cost associated with DR (per month), $      
First year after DR      
     Hospitalizations cost 2993 12 months 216 – 6273 LogNormal HA and CL 
     Physicians cost  314 12 months 166 – 462 LogNormal PC 
     Drugs cost  85 12 months 37 – 113 LogNormal DPIN 
After first year of DR      
     Hospitalizations cost 840 Lifetime 309 – 1361 LogNormal HA and CL 
     Physicians cost  257 Lifetime 153 – 362 LogNormal PC 
     Drugs cost  56 Lifetime 6 – 108 LogNormal DPIN 
€  Ranges used in sensitivity analyses were based on the same data sources as baseline values. Ranges used in sensitivity analyses of parameters 
estimated from the Manitoba Cancer Registry and administrative databases in Manitoba were based on observed confidence intervals. Ranges used 
in sensitivity analysis of parameters estimated from the retrospective analysis of the phase III SWOG-8814, INT-0100 trial were based on 
confidence intervals reported in this study. Ranges used in sensitivity analysis of utility estimates were based on arbitrary ranges reported in utility 
sources. 
†  Beta distribution was used for other probability parameter estimates not included in this table. 
‡  Utility estimates were based on visual analog scales (VAS). The baseline utility for post-menopausal women aged 50 to 80 was 0.824, based on 
representative values for the US population [155]. I derived utilities for each state by multiplying this baseline utility value by utility estimates for   
patients with breast cancer [150, 153, 156, 184] in the US, consistent with methodology as described by Fryback [154]. 
β   I used a disutility of 10% for a patient receiving chemotherapy with minor toxicity, a disutility of 30% for a patient receiving chemotherapy with 
major toxicity, and a disutility of 0% for patients receiving chemotherapy with no toxicity [153]. The disutility for major toxicity was applied to 
women experienced a major toxicity in our study population (i.e., 6% of our study population). A disutility average of 5% (i.e., average of 10% and 
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0% disutility estimates with minor toxicity and no toxicity respectively) was applied to all other women with minor or no toxicity. 
a Cost of breast cancer surgery: I used the Hospital Discharge Database and the Physician Claims Database to estimate the mean cost of 
hospitalization due to any breast cancer surgery (including one day hospitalization and using the ICD-9-Cprocedure codes for a hospital abstract) 
within one year after diagnosis with ESBC, LR and SPBC. 
b  Cost of radiation therapy: Cost of radiation therapy included cost of radiation therapy–related physician claims in addition to administrative cost. I 
used the Physician Claims Database to estimate the mean cost of radiation therapy–related physician claims (using the tariff code for a medical 
claim) within one year after diagnosis with ESBC, LR and SPBC. Administrative costs were derived from the cost list for Manitoba health services. 
c  Cost of endocrine therapy: I used the Drug Program Information Network (DPIN) to estimate the mean cost of tamoxifen and aromatase inhibitors 
(using the drug identification number (DIN) for a drug claim) within the time periods, between diagnosis with ESBC and before any relapse, 
diagnosis with LR and before any relapse, and diagnosis with SPBC and before any relapse. 
d  Cost of chemotherapy: Nursing, overhead and administration costs were derived from the cost list for Manitoba health Services. I used the 
Physician Claims Database to estimate the mean cost of chemotherapy–related physician claims costs (using thetariff code for a medical claim) 
within one year after diagnosis with ESBC, LR and SPBC. Chemotherapy regimens costs were estimated based on the market prices as of May 
2012. 
e  Weighted average cost of adjuvant chemotherapy regimens: I calculated the average cost of adjuvant chemotherapy regimens weighted to the 
observed proportion use of anthracyclines and taxane reported somewhere else [177]. Weighted average cost of adjuvant chemotherapy regimens = 
proportion of women received non-anthracyclines containing adjuvant chemotherapy × cost of CMF + proportion of women received anthracyclines 
containing adjuvant chemotherapy (no added taxanes) × cost of AC + proportion of women received anthracyclines and taxanes containing adjuvant 
chemotherapy × cost of TAC. 
f  Cost of CSAE: I used the Hospital Discharge Database and the Physician Claims Database to estimate the mean cost associate with 
hospitalizations due to any of the eight diagnoses which were considered CSAE among women who developed CSAE.  
g  Cost of surveillance: I defined the cost of breast cancer surveillance as the incremental cost of health care utilization (medical claims) after 
diagnosis with ESBC versus the time before diagnosis. I used the Physician Claims Database to collect medical claims for all women studied, within 
3 years before and 7 years after diagnosis wit ESBC. I estimated the mean cost of medical claims within 3 years before diagnosis in order to reflect 
the usual cost of health care utilization. I calculated the incremental mean cost of health care utilization during the period from diagnosis with ESBC 
and before any relapse (excluding cost of claims related to surgery, radiation therapy, chemotherapy, CSAE) stratified by the time from diagnoses 
(first year versus after). Similarly, I calculated the incremental mean cost of health care utilization after LR and SPBC. 
 
PSA= probabilistic sensitivity analysis; MCR= Manitoba Cancer Registry: PC= physician claims; HA= Hospital abstracts; CL= cost list for 
Manitoba health services; DPIN=Drug Program Information Network records; ESBC= early stage breast cancer; LR, loco-regional recurrence; DR= 
distant recurrence; SPBC=second primary breast cancer; CMF= 6 cycles of cyclophosphamide, methotrexate, 5-fluorouracil; AC= 4 cycles of 
doxorubicin, cyclophosphamide; FAC= 6 cycles of fluorouracil, doxorubicin, cyclophosphamide; TAC= 6 cycles of docetaxel, doxorubicin, 
cyclophosphamide; CCP= current clinical practice; CSAE= chemotherapy-related serious adverse effects; RS= recurrence score. 
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4.3.4 Adjuvant Chemotherapy Regimens and Adjuvant 
chemotherapy-related Serious Adverse Effects 
Data on specific chemotherapy agents are not collected by the MCR and Manitoba 
administrative databases. I was able to ascertain a non-anthracycline-, anthracycline- or 
taxane-containing chemotherapy regimen by linking with the Physician Claims Database 
and identifying the specific tariff index for services relating to those agents as described 
elsewhere [177]. I considered patients who received non-anthracycline-containing 
adjuvant chemotherapy regimens received 6 cycles of cyclophosphamide, methotrexate, 
5-fluorouracil (CMF); that patients who received anthracycline-containing adjuvant 
chemotherapy regimens with no added taxanes received four cycles of doxorubicin 
(Adriamycin), cyclophosphamide (AC); and that patients who received anthracycline and 
taxane-containing adjuvant chemotherapy regimens received 6 cycles of docetaxel, 
doxorubicin, cyclophosphamide (TAC). In Canada, these three adjuvant chemotherapy 
regimens were available for women with ER+ or PR+ 1-3 LN+ ESBC during the time 
period of 2000-2003 [176-177]”. In the base case analysis I used the weighted average 
cost of CMF, AC and TAC. In sensitivity analysis I considered each of these regimens 
separately as the standard adjuvant chemotherapy regimen for postmenopausal women 
with ER+ or PR+ 1-3 LN+ ESBC. I linked the study population with the Hospital 
Discharge Database in order to estimate the rate of adjuvant chemotherapy-related 
serious adverse effects (CSAE) using the method developed by Charlson et al. excluding 
cancer diagnoses [165] as described in detail elsewhere [181].  
4.3.5 Cost and Utility Values 
According to the Annual Report Card of the Cancer Advocacy Coalition of Canada, the 
RS-assay will cost $4,000 CAD per patient including all Canadian system expenses 
[124]. I estimated all relevant treatment costs for ESBC including the cost of surgery, 
radiation therapy, chemotherapy, and endocrine therapy, and the cost of CSAE 
management and surveillance over 7 years following diagnosis. All these treatments are 
publically funded in Manitoba and recorded in Manitoba health databases. I used these 
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cost estimates to derive the cost per unit time in each Markov state (Table 6). All costs 
are expressed in 2012 CAD using the bank of Canada inflation calculator [185]. 
I assumed a baseline utility of 0.824 for postmenopausal women in order to account for 
background morbidity [155]. I multiplied the baseline utility by utility estimates for 
women with breast cancer [150, 153-154, 156, 184] to calculate utilities across health 
states (Table 6). I examined the impact of potential long term side effects of adjuvant 
chemotherapy on health related-quality of life [166] by performing sensitivity analysis on 
utility values following adjuvant chemotherapy. 
4.3.6 Analysis 
The cost-effectiveness analysis was conducted according to recommendations by the 
Canadian Agency for Drugs and Technologies in Health [111]. Results are presented in 
the form of cost-effectiveness ratio (ICER) which provides a measure of average cost per 
additional unit of health benefit. Outcomes for health effects are measured in QALYs 
(i.e., life-years weighted by utility estimates to produce QALYs). Cost outcomes were 
measured as the mean cost per patient. To characterize uncertainty in the output 
measures, I conducted one and two-way deterministic sensitivity analyses on parameters 
of interests. In addition, I conducted probabilistic sensitivity analysis using Monte Carlo 
simulation with 1000 iterations. Each iteration consisted of a random draw from an 
appropriate distribution for all model inputs to produce a distribution of model outputs. 
I conducted value-of-information analysis [112] to determine the expected monetary 
value of perfect information about the RS-assay in the Canadian setting. In particular, I 
set up our baseline model to express RS-assay related parameters (i.e., risk classification 
by RS-assay, adjuvant chemotherapy assignment following RS-assay and probabilities of 
first relapse following RS-assay) as probability distributions (i.e., reflecting uncertainty 
of the RS-impact in the Canadian setting) on the basis of retrospective analysis of the 
phase III SWOG-8814, INT-0100 trial [20] and the entire model is set up as a 
probabilistic model. Using simulation techniques (i.e., making random draws of the 
probabilistic model), the level of uncertainty in the model is assessed. Using a 
willingness to pay threshold of $100,000 per QALY gained [69], the opportunity cost 
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associated with the choice of RS-assay as the optimal strategy for guiding adjuvant 
therapy is calculated and presented as a total of expected value of perfect information 
(EVPI) about the RS-assay per patient. Using the size of ER+ or PR+ 1-3 LN+ ESBC 
population, one can calculate the EVPI about the RS-assay for the entire target population 
that could potentially benefit from more research on the predictive value of the RS-assay 
in the Canadian setting. In particular, the EVPI may provide decision makers with 
valuable information about the use of novel funding models such as conditional funding 
alongside a field evaluation [113]. 
4.4 Results 
Patient, tumor, treatment and event characteristics of the study cohort are reported 
elsewhere [177]. There were 161 post-menopausal women diagnosed with ER+ or PR+ 
1-3 LN+ ESBC during the period from January 1, 2000 to December 31, 2002 in 
Manitoba. The median patient age was 61 years (range 50–89 years). The majority of 
women (95%) received surgery (mastectomy or lumpectomy) for their primary breast 
cancer. Radiation therapy, endocrine therapy (tamoxifen or aromatase inhibitors) and 
chemotherapy were administered in 60%, 89% and 64% of women respectively. The RS-
assay led to an increase of 0.08 QALY per person and an increase in cost of $36.2 CAD 
per person, resulting in an incremental cost effectiveness ratio (ICER) of $464 per QALY 
gained (Table 7). 
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Table 7. Baseline outcomes†. 
Strategy Effectiveness Incremental Effectiveness Cost 
Incremental 
Cost ICER 
CCP 15.73 QALY 0.08 QALY $49093.0  $36.2  $464 per QALY gained RS-assay 15.81 QALY $49129.2  
† Due to rounding, numbers may not balance 
CCP= current clinical practice; RS=recurrence score; ICER= incremental cost effectiveness ratio; QALY= quality 
adjusted life year.  
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4.5 Sensitivity Analyses 
In the base case I compared the RS assay versus CCP when the weighted average cost of 
CMF, AC and TAC was used. I considered each of CMF, AC, and TAC regimens 
separately as the standard adjuvant chemotherapy regimen for women with ER+ or PR+ 
1-3 LN+ ESBC in sensitivity analysis. The RS-assay had an ICER of $4,150 per QALY 
gained with CMF, $152 per QALY gained with AC, and was cost saving with TAC. The 
utility during chemotherapy and the rates and costs of CSAE did not substantially 
influence our baseline results (Table 8). 
I performed threshold analyses on the proportion of chemotherapy-treated women in the 
intermediate risk group by the RS-assay, risk of relapse in the RS-assay model, and 
several other parameters (Table 8). The RS-assay generated negative cost and effect (the 
RS-assay led to decrease in cost and effect) when fewer than 36% of women in the RS-
assay intermediate risk group received adjuvant chemotherapy. If the absolute risk of 
relapse in the RS-assay model increased by approximately 2.6% then RS-assay would be 
dominated by CCP. 
I performed a probabilistic sensitivity analysis (Figure 4a) comparing the RS-assay 
versus CCP. I simultaneously varied all parameters (probabilities, utilities and costs) 
using appropriate distributions (Table 6). Using a willingness to pay threshold of 
$100,000 per QALY gained, I found that the RS-assay was the preferred strategy in 72% 
of simulations (Figure 4b).  
I also performed a value-of-information analysis in which I estimated the expected 
value of removing all statistical uncertainty of the RS-assay related parameters [112]. 
This type of analysis is necessary to estimate, in monetary values, the societal impact of 
future research that can evaluate the RS-assay in real life Canadian clinical practice. 
Using a willingness to pay threshold of $100,000 per QALY gained, the opportunity cost 
associated with the choice of RS-assay as the optimal strategy for guiding adjuvant 
therapy resulted in a total of EVPI of $4,200 per post-menopausal woman with ER+ or 
PR+ 1-3 LN+ ESBC. Subsequently, I estimated the expected value for the entire ER+ or 
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PR+ 1-3 LN+ ESBC population that could potentially benefit from more research on the 
predictive value of the RS-assay in the Canadian setting. In Manitoba, there were 
approximately 80 women diagnosed with ER+ or PR+ 1-3 LN+ ESBC. Based on the size 
of Manitoba relative to the rest of Canada, I anticipate a total of approximately 2216 
postmenopausal women diagnosed with ER+ or PR+ 1-3 LN+ ESBC who would be 
eligible for the 21 gene assay in Canada. The resulting population EVPI was more than 
$9.3 CAD million per year.
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Table 8. Summary of important one-and two way sensitivity analysesa. 
 Interpretation of the incremental impact of the RS-assay compared to CCP 
 
 
Variable (range tested) 
Negative 
cost and 
effect 
 
 
 
Cost savings 
ICER  in the 
range 
0 to < 20,000 
$/QALY gained 
ICER in the range 
≥ 20,000 to ≤100,000 
$/QALY gained 
ICER in the range 
> 100,000 $/QALY 
gained 
Dominated 
Chemotherapy treated women in 
intermediate risk group by the RS-assay 
(0% to 100%) 
0% to 36% 37% to 47% 48% to 100%    
Change in absolute risk of relapsebin the 
RS-assay model(-10% to +10%)   <+2.2% ≥ +2.2% to ≤ 2.3% > +2.3% to ≤+2.6% > +2.6% 
 
 
Change in utility 
of recurrencec 
and SPBR 
(-10% to +10%) 
 
Lower limit cost of 
recurrencec and SPBR   
 
≤ -6% 
 
> -6%   
Baseline cost of 
recurrencec and SPBR   -10%  to +10%    
Upper limit cost of 
recurrencec and SPBR  -10% to+10%     
Change in utility during adjuvant 
chemotherapy  
(-20% to 0%) 
  -20% to 0%    
Change in utility following adjuvant 
chemotherapy (-10% to +10%)   ≤ +1.5% +1.6% to <+2 % ≥+2% to ≤+2.2% > +2.2% 
Chemotherapy-related serious adverse 
effects (0% to 14.6%)   (0% to 14.6%)    
     Cost of chemotherapy-related serious 
adverse effects ($1376  to $2168 )   ($1376 to $2168)    
CCP= current clinical practice; SPBR= second primary breast cancer; RS=recurrence score;  
aValuesin the table show how the incremental impact of the RS-assay compared to CCP changes, over 6 significant ranges, depending on the values of certain 
key parameters. For example, if between 37%-47% of women identified as intermediate risk by the RS-assay were to receive chemotherapy, then the RS-assay 
would be cost saving relative to CCP; if this proportion is 48% or greater, then the RS-assay has an ICER between 0 and $20,000 / QALY gained. 
bRelapse includes loco-regional recurrence, distant recurrence, SPBR and death due to any cause. 
cRecurrence includes loco-regional and distant recurrences. 
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Figure 4. Incremental cost-effectiveness scatterplot and acceptability curve of recurrence 
score (RS)-assay versus CCP-guided therapy. Sampling distributions and summary 
estimates of cost, efficacy, and variance were based on 1000 replicates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
Incremental Cost Effectiveness Scatter plot of RS-assay versus CCP 
 
b 
Cost-Effectiveness Acceptability Curve of RS-assay versus CCP 
 
 
          CCP 
         RS-assay 
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4.6 Discussion 
I developed a decision-analytic model to evaluate the cost effectiveness of the RS-assay 
versus CCP in post-menopausal women with ER+ or PR+ 1-3 LN+ ESBC. In the base 
case, I estimated that the RS-assay has an ICER of $464 per QALY gained. Our ICER 
estimate is significantly lower than $20,000 per QALY gained, a level which has been 
suggested in Canada to define “strong evidence in support of adoption” [69] and below 
levels of recently adopted cancer treatments (e.g., [169-170]). 
Previous cost-effectiveness analyses of the RS-assay in LN+ disease population have 
several limitations and may not be applicable in the Canadian context. Two studies did 
not incorporate results from the retrospective analysis of the phase III SWOG-8814, INT-
0100 trial [20], which established the relationship between the RS-assay and the benefit 
from using chemotherapy in the LN+ disease setting. One of these analyses [130] was 
based on data from the National Surgical Adjuvant Breast and Bowel Project (NSABP) 
B20 trial for LN- disease [11] with relevant adjustments for baseline relapse risk and 
reported a favourable ICER of$5,685 USD per QALY gained in a subset analysis 
involving LN+ disease. The second analysis [182] found the RS-assay to be cost saving 
in LN+ disease setting due to predicted reductions of chemotherapy utilization after RS 
testing, but did not employ specific disease outcomes according to RS risk groups. One 
recent study has incorporated specific disease outcomes from the retrospective analysis of 
SWOG 8814trial. However, modeling the current experience of LN+ disease (i.e., 
without the RS-assay) with regard to survival in this study was not based on Canadian 
data and did not reflect real world clinical practice, and the model did not incorporate all 
breast cancer complications such as second primary breast cancer [132-133]. More 
importantly, the study did not focus on the low risk subset of LN+ disease setting (1-3 
LN+) for whom the RS-assay is likely to be used in real life clinical practice and instead 
considered women with all levels of nodal involvement to be eligible for the RS-assay. 
There is no robust Canadian or international data yet to suggest that women with 
extensive nodal involvement (i.e., ≥ 4LN+) would not benefit from a treatment strategy 
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including chemotherapy [186]. Thus, the RS-assay may have no clinical utility for these 
women.  
Our finding is consistent with earlier analyses of the RS-assay in the LN- disease setting. 
The ICER of the RS-assay in post-menopausal women with ER+ or PR+ 1-3 LN+ ESBC 
was within ICER ranges of the assay in women with LN- disease in Canada. For instance, 
in a recent analysis the RS-assay compared to CCP in LN- patient population generates 
cost-savings in pre-menopausal women and has an ICER of $60,000 per QALY gained in 
post-menopausal women (2012) [181]. Other ICER estimates for LN- disease in Canada 
are at $9,591 (2012) [133] and $63,064 (2010) [132] per QALY gained. 
As of January 2013, the test is not publically funded for women with 1-3 LN+ disease in 
any Canadian province and these women are not currently eligible for inclusion in 
ongoing field evaluations of the RS-assay [186]. However, unlike the use of the RS-assay 
in LN+ disease, the use of the assay in LN- disease with reimbursement mechanisms is 
increasing across Canada. It became available for women with LN- disease in several 
provinces in a limited fashion or within context of a field evaluation [124-126]. Our value 
of information analysis in ER+ or PR+ 1-3 LN+ ESBC setting demonstrated that future 
research that can characterize the role of the RS-assay in real world Canadian practice 
may have a large societal impact, when willingness to pay levels of recently accepted 
cancer treatments are considered. Taken together with recent Canadian findings [177] on 
adjuvant chemotherapy efficacy in this particular patient population, this suggest that 
future field evaluations of the assay to establish its impact on Canadian practice should 
include postmenopausal women with 1-3 LN+ disease in addition to women with LN- 
disease. 
The results of the retrospective analysis of SWOG 8814trial [20]are the first and only 
findings that indicate the prognostic utility of the RS-assay in LN+ disease population 
receiving tamoxifen alone. Our model was sensitive to the disease specific outcomes by 
the RS-assay derived from this analysis particularly for women included with 1-3 LN+ 
disease. Additionally, our analysis demonstrated that the ability of the RS-assay to guide 
treatment decisions in the intermediate risk group will likely be important in determining 
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whether the RS-assay will be a cost-effective use of resources. An ongoing prospective 
randomized trial (SWOG S-1007) [26] will determine the effect of chemotherapy in 
patients with 1-3 LN+ disease who do not have high RS by RS-assay. This trial will 
provide new evidence regarding the clinical utility of the RS-assay in this particular 
disease setting and further assess the predictive value of the assay in women falling in the 
intermediate risk group. However, findings from this trial will not be available for 5 years 
whereas an adoption decision will need to be made prior to having the results of this trial. 
I used the Manitoba Cancer Registry and Manitoba Health administrative databases to 
model current real-world Canadian clinical practice. This approach may increase model 
complexity but it has the advantage of providing us with longitudinal patient, clinical and 
treatment data on a large number of patients and for a long follow up time (7 years). This 
allows us to estimate significant clinical outcomes (e.g., local recurrence, regional 
recurrence, second primary, chemotherapy-related serious adverse effects) that are 
otherwise hard to model using secondary data sources. This approach to decision 
modeling and cost-effectiveness analyses have been considered helpful in identifying 
data needs and quantifying uncertainty about a new medical intervention in the “real 
world” Canadian setting [187]. A more thorough discussion of the use of  registry and 
administrative data to conduct cost-effectiveness analyses in the Canadian setting has 
been discussed elsewhere [188]. 
This study has limitations. First, the clinical utility of the RS- assay in women with 1-3 
LN+ disease was based on retrospective analysis of the phase III SWOG-8814, INT-0100 
trial conducted in the United States [20]. Thus, disease outcomes by the RS-assay may 
not necessarily reflect the experience of the ER+/PR+ 1-3 LN+ ESBC identified in 
Manitoba due to potential differences in patient and tumor characteristics and treatments. 
In regard to this shortcoming, reports from prospective analyses of the assay in real-world 
Canadian clinical practice are awaited to update our model and verify our results. Second, 
clinical guidelines are still awaited for women with intermediate-range RS-assay values 
[26]. Third, outcomes and costs of therapies given in the 2000-2002 population do not 
necessary reflect the possible benefits and costs of other newer types of adjuvant 
therapies (e.g., third generation anthracycline-taxane regimens) or dosing schedules used 
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in current practice so analysis with such data would be more applicable to the current 
practice landscape. Finally, although clinical practice patterns employed in the selected 
time period in Manitoba have shown to reflect practices in other jurisdictions in Canada 
[88, 174-175], management of women with ER+/PR+ 1-3 LN+ ESBC and its associated 
costs may be still different.  
4.7 Conclusion 
The RS-assay compared to CCP is likely to be cost-effective in postmenopausal women 
with ER+ or PR+ 1-3 LN+ ESBC. Current use of the assay with public reimbursement 
mechanisms should be extended to include cases with 1-3 LN+ disease in addition to LN- 
cases. Field evaluations of the assay to establish its impact on CCP in women with 
ER+/PR+1-3 LN+ ESBC should be initiated to ensure its clinical utility and cost-
effectiveness in this patient population. 
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Chapter 5  
5 Cost-effectiveness of using a microarray-based gene 
expression test to aid in identifying primary tumor 
versus Canadian clinical practice in patients with cancer 
of unknown primary 
5.1 Abstract 
A microarray-based gene expression test called the tissue of origin (TOO) test provides a 
method to predict the likely primary tumor site in cancer of unknown primary (CUP) by 
testing the biopsy specimen of the metastatic tumor. I sought to investigate the cost-
effectiveness of using the TOO test to help identify primary tumor versus current clinical 
practice (CCP) in patients with CUP from the perspective of the Canadian public 
healthcare system. I developed a decision analytic model to project the lifetime clinical 
and economic consequences of CUP. I assumed that CUP patients present with occult 
primary tumor sites. Within each occult primary tumor setting, the TOO test may either 
lead to tumor specimen classification or indeterminate results. I assumed that TOO tumor 
classification would be interpreted after careful clinicopathologic and radiologic 
assessment and this may lead to correctly or incorrectly diagnose primary tumor or 
primary tumor stays undiagnosed, and correspondently guide patient management. The 
model was parameterized using 2 year follow up data from the Manitoba Cancer 
Registry, cost data from Manitoba Health administrative databases and secondary 
sources. Costs are presented in 2013 Canadian dollars (CAD), and future costs and 
benefits were discounted at 5%. In the base case, the TOO-based strategy compared to 
CCP led to an increase of 0.28 life year (LY) and 0.24 quality-adjusted life year (QALY) 
and an increase in cost of $10,807 CAD per person, resulting in an incremental cost 
effectiveness ratio (ICER) of $37,774 per LY gained and $44,151 per QALY gained. The 
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ICER was most sensitive to the accuracy of the TOO test, diagnostic results following 
TOO tumor classification and patient survival response following correct primary 
diagnosis. The TOO test is likely to be cost effective in the Canadian healthcare system 
and should be considered for adoption in patients with CUP. However, field evaluations 
of the test to establish its impact on Canadian management of CUP and resulting survival 
outcomes are warranted for further investigation. 
5.2 Introduction 
The Canadian Cancer Society estimates that approximately 186,400 new cases of cancer 
will occur in Canada in 2013 [189]. Of these new cases, up to 4% are of metastatic cancer 
types not readily classified in the course of the initial diagnostic work up which includes 
careful exanimation of clinical history, full physical examination (including head and 
neck, breast, pelvic and rectal examination) and chest radiograph [190]. International and 
Canadian clinical guidelines recommend a further diagnostic work-up for these metastatic 
patients including blood and biochemistry survey, urinalysis, fecal occult blood test, 
imaging procedures, cytogenetic studies, electron microscopy and immunohistochemical 
(IHC) analysis [190]. Additional evaluation and endoscopies are recommended to be 
sign-or symptom-guided [190]. In the past decade, improvements in the number and 
accuracy of IHC stains have enabled to make highly accurate tissue-of-origin diagnosis in 
many of these metastatic patients. However, the current success rate of the diagnostic 
work-up, even after exhaustive clinical and pathologic investigation, varies from 20% to 
25% [39, 41]. Consequently, over 3% of all incident cancer cases are metastatic cancer of 
unknown primary origin (CUP) recorded annually in tumor registries across Canada, 
accounting for approximately 5000-7000 cases of CUP annually. The majority of these 
CUP cases were proven by autopsy series to have small clinically undetectable (i.e., 
occult) primary tumor sites [191]. 
In the absence of a specific tumor diagnosis, there has been no consensus of defined 
treatment guidelines. Several broad-spectrum empiric chemotherapeutic regimens (not 
specific for the nature of cancer) based on combination regimens of platinum or taxane 
have generally been used [192-193]. However, patients have a poor prognosis with a 
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median survival of 8-12 months from diagnosis and 1-year survival probabilities ranging 
from 15% to 35% [41]. 
The ability to identify a primary tumor site has been and continues to be the most 
important goal in the clinical management of any patient with metastatic cancer. When 
tumor origins are known, patient outcomes and even survival may improve [194-195]. 
This is because oncologists have better information on which to base treatment strategies 
and can allow patients to benefit from the increasing availability of specific and more 
effective therapy regimens, which may include specific chemotherapy or therapy 
designed to target biologic characteristics of specific malignancies. 
Prediction of the likely primary tumor site by testing the biopsy specimen of the 
metastatic tumor is improving through the use of gene expression profiling techniques 
[196-197]. To date, several gene expression-based tests have demonstrated the potential 
value of this approach in identifying the primary site. However, only one test called “the 
Tissue of Origin (TOO)” test is clinically viable option and fulfill criteria for successful 
translation [54-55] according to publically available evidence [48, 59]. The TOO test 
(Response Genetics, Inc., Los Angeles, CA) is a microarray-based gene expression test 
for identifying a tumor’s primary site using formalin-fixed paraffin-embedded (FFPE) 
specimens. The test compares the RNA profile of a tumor FFPE specimen to established 
RNA profiles of 15 known tissues. The test measures the degree of similarity between the 
expression patterns of the tumor and those of a panel of 15 different tissue types. The 
TOO test result is presented as 15 separate similarity scores (SS) (which are interpreted 
as probabilities), one for each tissue type on the panel. The highest SS indicates the most 
likely tissue of origin. An SS of 30 or less indicates indeterminate results. When a 
specimen is found to include less than 60% of tumor content and more than 20% necrosis 
the TOO test results are considered indeterminate regardless of SS. 
The test was validated on independent 462 formalin-fixed paraffin-embedded (FFPE) 
specimens derived from metastatic or poorly differentiated tumor specimens of known 
primary cancers and showed 89.3% accuracy in identifying tumor’s primary site [59]. 
The analysis included at least 25 specimens per tissue type and considered indeterminate 
results. In  2012, the test was reviewed and cleared by the Food and Drug Administration 
and has been clinically offered in the United States [60]. The TOO test results are 
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intended for use in the context of the patient’s clinicopathologic and radiologic history by 
a qualified oncologist and pathologist [198-200]. For instance, initial or additional 
clinical history, IHC analyses, and computed tomography (CT) scan images should be 
correlated and consistent with TOO tumor classification when suggesting a potential 
primary tumor site. 
The impact of the test on health and economic outcomes, if introduced into general 
clinical practice for CUP patients, has not been determined. The TOO test has official list 
price of $4,400 CAD per patient. As of January 2014, the test is not publically funded in 
any Canadian province and clinical management of CUP patients has not been influenced 
by TOO testing. Developing recommendations for Canadian clinical practice regarding 
the use of TOO test in CUP requires a comprehensive health economic evaluation of this 
approach in the Canadian setting [69]. I sought to evaluate the cost-effectiveness of using 
the TOO test to help diagnose the primary tumor and guide treatment decisions compared 
to current clinical practice (CCP) in patients diagnosed with CUP from the perspective of 
the Canadian health care system. 
5.3 Methods 
5.3.1 Model Overview 
I developed a decision analytic model (Figure 5) to estimate the lifetime clinical and 
economic consequences of different clinical management strategies for patients 
diagnosed with CUP. The model begins with a decision to use the TOO test or to 
continue with CCP (Figure 5a). In the CCP-based strategy (Figure 5b), I classified CUP 
patients according to their occult primary tumor sites. Within each occult primary tumor 
site, I assumed that patients are treated according to existing clinical guidelines when 
primary tumor site stays undiagnosed. In the TOO-based strategy (Figure 5c), I classified 
CUP patients according to their occult primary tumor sites. Within each occult primary 
tumor site I assumed that the TOO test results would either classify the tumor specimen 
to one of the 15 tissue types included in the test panel or lead to indeterminate results 
(i.e., when SS is ≤ 30, encounter unique specimens harboring less than 60% tumor 
content, or actual tissue of origin for a given tumor specimen is not covered by the 15 
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tissue types included in the test panel) (Figure 5c). When TOO test results classify the 
tumor specimen, these results would either be correct or incorrect. I assumed that TOO 
tumor classification would be interpreted after careful clinicopathologic and radiologic 
assessment (CRA). When clinicopathologic correlation can be established with TOO test 
results (i.e., correct or incorrect), I assumed that TOO tumor classification would be 
considered and may lead to correct or incorrect cancer diagnosis and guide treatment 
decisions (Figure 5c). When clinicopathologic correlation cannot be established with the 
TOO test results (i.e., correct or incorrect), I assumed that TOO tumor classification 
would not be considered and primary tumor may stay undiagnosed (Figure 5c). 
CUP patients whose primary tumor stays undiagnosed in both strategies or those who 
have their primary tumor incorrectly diagnosed in the TOO-based strategy entered model 
“A” (Figure 5d). CUP patients who have their primary tumor correctly diagnosed in the 
TOO-based strategy entered model “B” (Figure 5e). Model “A” differs from model “B” 
in that it has an additional health state to account for possible detection of an eventual 
primary tumor later during the course of the disease (latent primary). 
Model “A” simulated monthly transitions among the following five distinct health states: 
(1) Initial diagnosis of metastasis (IDM); (2) diagnosis of latent primary (LP); (3) 
diagnosis of second primary (SP); (4) palliative care (PC); (5) death. Model “B” 
simulated monthly transitions among the following four distinct health states: (1) IDM; 
(2) SP; (3) PC; (4) death. 
The analysis was conducted from the Canadian health care payer’s perspective. I applied 
a discount rate of 5% per annum to costs, life years (LY) and quality adjusted life years 
(QALYs) following recommendations by the Canadian agency for Drugs and 
Technologies in Health [111]. I used a lifetime horizon and half cycle correction [136]. I 
used TreeAge Software to populate and evaluate the decision analytic model [136]. Data 
collection and analysis using Manitoba administrative databases (including the Manitoba 
Cancer Registry, the Hospital Discharge Database, the Physician Claims Database and 
the Drug Program Information Network) were approved by the University of Manitoba 
Health Research Ethics Board and Western University Health Research Ethics Board. 
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Figure 5. Decision model for CUP. 
a TOO testversus CCP-guided clinical management. 
 
b CCP-guided clinical management. 
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c TOO-guided clinical management. 
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d Schematic representation of the Markov model structure “A”. 
 
e Schematic representation of the Markov model structure “B”. 
 
 
      Decision node         Chance node             Transition  
Patients entering Markov model “A” start the model and remain in the IDM state unless they develop LP or SP, start PC, or die. 
Patients who developed LP remain in the LP state or make transition to SP, PC, or Dead states.  Patients entering Markov model 
“B” start the model and remain in the IDM state unless they develop SP, start PC, or die. In both Markov models, patients who 
developed SP, remain in the SP state or make transition to PC or Dead states. Patients who started PC remain in the PC state or 
make transition to Dead state. The cycle length was 1 month. Abbreviations: CCP= Canadian clinical practice; TOO= Tissue of 
Origin; CRA= clinicopathologic and radiologic assessment; IDM= initial diagnosis of metastasis; LP= diagnosis of latent 
primary; SP= diagnosis of second primary; PC= palliative care. 
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5.3.2 Identification of a Study Cohort 
The MCR is a provincial database that contains the records for more than 99.5% of all 
cases of cancer in Manitoba and is a comprehensive cancer registry [137]. Information on 
cancer staging, based on the American Joint Commission on Cancer (Version 5), has 
been routinely collected for all cancer sites since January 1995 [138]. The MCR also 
collects information on demographics, clinical tumor characteristics, disease progression, 
SP cancer, death, and cancer treatments.  I used the MCR to identify a study cohort 
consisting of all metastatic cancer patients (defined as diagnosed initially with stage IV or 
diagnosed with distant metastasis within 4 months of initial diagnosis) during the period 
from January 1, 2002 to December 31, 2011. I limited the study cohort to those who are 
Manitoba residents, 18 to 90 years old and with no history of malignancy at initial 
diagnosis. Since the end of the accrual period is 2011, a minimum of two-year follow-up 
information from the time of initial diagnosis was available for each patient. This 
included diagnosis of SP, cancer treatments (e.g., surgical procedures, therapeutic 
radiology procedures, endocrine therapy, chemotherapy, biological therapy, and palliative 
care) and death. I linked all patients with administrative data held by Manitoba Health 
including the Hospital Discharge Database, the Physician Claims Database and the Drug 
Program Information Network. To protect confidentiality, the linkage was performed 
with a scrambled health number using anonymatized versions of these databases.  
For each patient in our study cohort, I used the MCR to establish the initial diagnosis 
status of primary tumor site. I used initial tumor specific-files (i.e., historical data) 
available on cancer patients in the registry and search for codes representing the 
anatomical sites (i.e., using the International Classification of Diseases for Oncology 
(ICD-O) topography diagnosis codes). I linked all patients with their tumor specific-
updated files available in the MCR (i.e., linkage performed via both tumor ID and 
scrambled health number). I then identified those who have their initial primary 
anatomical site status changed to different site at least 6 months after their initial 
diagnosis. This 6 month window is considered necessary and reasonable to ensure that 
the diagnoses of the later primary anatomical sites were not the results of extension in the 
initial diagnostic work up [10]. I considered these patients to have a LP tumor site 
subsequently detected during their life or at autopsy. 
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I stratified our study cohort to three patient groups; (1) metastatic patients diagnosed 
initially with CUP: defined as those who were initially diagnosed with CUP (i.e., using 
the ICD-O topography diagnosis code c80.9) and either had their LP detected or 
undetected later during their life or at autopsy; (2) metastatic patients diagnosed initially 
with their true primary site: defined as those who were initially diagnosed with known 
primary and had no change detected with their primary diagnosis later during their life or 
at autopsy); (3) metastatic patients diagnosed initially with their incorrect primary site: 
defined as those who were initially diagnosed with a given known primary and had a LP 
detected later during their life or at autopsy).  For each patient group, I ascertained PC 
from both the MCR and by linking with the Physician Claims Database and using the 
specific tariff index of PC as provided by physicians. 
5.3.3 Distributions and Transition Probabilities 
I defined CCP for CUP according to the observed administration of treatments and 
survival outcomes in metastatic patients diagnosed initially with CUP (i.e., patient group 
“1”). I conducted survival analyses using Kaplan-Meier estimates using 2 years of follow 
up data from the MCR, and used this information to estimate all transition probabilities in 
the CCP Markov model “A”. 
For the TOO model I estimated the distribution of occult primary tumor sites among CUP 
patients (Table 9) based on the observed distribution of LPs among the subset of patients 
initially diagnosed with CUP who had their LP tumor site subsequently detected during 
their life or at autopsy. For each occult primary tumor site in the TOO model, I extracted 
the distribution of patients across TOO test results (i.e., classification of tumor specimen 
(correct and incorrect) or indeterminate results) and across diagnostic results after CRA 
(correct diagnosis of primary, incorrect diagnosis of primary, and undiagnosed primary) 
from a recent validation analysis [59] and clinical verification of the TOO test 
performance [198] (Table 9). 
I assumed that CUP patients whose primary is correctly diagnosed would have survival 
outcomes similar to those of observed metastatic patients diagnosed initially with their 
true primary site [191]. Thus, I conducted survival analyses using Kaplan-Meier 
estimates for metastatic patients diagnosed initially with their true primary site (i.e., 
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patient group “2”). I stratified this analysis by primary tumor site, using 2 years of follow 
up data from the MCR, and used this information to estimate all transition probabilities in 
the TOO Markov models following the chance nodes when the primary is correctly 
diagnosed. I assumed that CUP patients whose primary stays undiagnosed or is 
incorrectly diagnosed would have survival outcomes similar to those of observed 
metastatic patients diagnosed initially with CUP(i.e., patient group “1”) [191]. 
To extrapolate transition probabilities for lifetime, I assumed the observed average 
monthly transition probabilities during the last observed year of follow up in the studied 
population to be constant over the extrapolated time period. However, projected survival 
beyond 2 years was low in our metastatic patient population.   
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Table 9. Base case probabilities and sources. 
 
Variables  
Base 
case 
Value 
Duration 
Range tested 
in sensitivity 
analyses 
Distribution 
used in PSA† Data Source 
Distribution of occult primary tumor sites among CUP patients 
(%)     MCR 
 Bladder 0   Dirichlet  
 Breast  1.5   Dirichlet  
 Colorectal 8.9   Dirichlet  
 Gastric 3.8   Dirichlet  
 Testicular germ cell 0.5   Dirichlet  
 Kidney 3.5   Dirichlet  
 Hepatocellular 1   Dirichlet  
 Non-small cell lung  27   Dirichlet  
 Non-Hodgkin’s lymphoma 5.3   Dirichlet  
 Melanoma 4.56   Dirichlet  
 Ovarian 9.6   Dirichlet  
 Pancreas 8.9   Dirichlet  
 Prostate  1.5   Dirichlet  
 Sarcoma 1.27   Dirichlet  
 Thyroid  0.76   Dirichlet  
 Others 21.91   Dirichlet  
Distribution of patients according to classification provided by 
the TOO within each occult primary tumor site (%)     [59] 
 Bladder      
  Classification of tumor specimen 93  90 – 100  [198] 
   Incorrect classification 79.3  60.3 – 92  [59] 
   Correct classification 20.7  8 – 39.7 Beta [59] 
  Indeterminate results  7  0 – 10 Beta [198] 
 Breast      
  Classification of tumor specimen 93  90 – 100  [198] 
   Correct classification 96.5  87.9 – 99.6  [59] 
   Incorrect classification 3.5  0.4 – 12.1 Beta [59] 
  Indeterminate results 7  0 – 10 Beta [198] 
 Colorectal      
  Classification of tumor specimen 93  90 – 100  [198] 
   Correct classification 91.7  77.5 – 98.2   [59] 
   Incorrect classification 8.3  1.8 – 22.5 Beta [59] 
  Indeterminate results  0  0 –10 Beta [198] 
 Gastric      
  Classification of tumor specimen 93  90 – 100  [198] 
   Correct classification  72  50.6 – 87.9  [59] 
   Incorrect classification 28  12.1 – 49.4 Beta [59] 
  Indeterminate results  7  0 –10 Beta [198] 
 Hepatocellular      
  Classification of tumor specimen  93  90 – 100  [198] 
   Correct classification 96  79.6 – 99.9  [59] 
   Incorrect classification 4  0.1 – 20.4 Beta [59] 
  Indeterminate results  7  0 –10 Beta [198] 
 Germ cell      
  Classification of tumor specimen  93  90 – 100  [198] 
   Correct classification 84  63.9 – 95.5  [59] 
   Incorrect classification 16  4.5 – 36.1 Beta [59] 
  Indeterminate results  7  0 –10 Beta [198] 
 Kidney      
  Classification of tumor specimen  93  90 – 100  [198] 
   Correct classification 89.3  71.8 – 97.7  [59] 
   Incorrect classification 10.7  0.3 – 28.2 Beta [59] 
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  Indeterminate results  7  0 –10 Beta [198] 
 Melanoma      
  Classification of tumor specimen 93  90 – 100  [198] 
   Correct classification 84  63.9 – 95.5  [59] 
   Incorrect classification 16  0.5 – 36.1 Beta [59] 
  Indeterminate results  7  0 –10 Beta [198] 
 Non-Hodgkin’s lymphoma      
  Classification of tumor specimen 93  90 – 100  [198] 
   Correct classification 89.7  72.6 – 97.8  [59] 
   Incorrect classification 10.3  2.2 – 27.4 Beta [59] 
  Indeterminate results  7  0 –10 Beta [198] 
 Non-small cell lung       
  Classification of tumor specimen  93  90 – 100  [198] 
   Correct classification  85.2  66.3 – 95.8  [59] 
   Incorrect classification 14.8  4.2 – 33.7 Beta [59] 
  Indeterminate results  7  0 –10 Beta [198] 
 Ovarian      
  Classification of tumor specimen 93  90 – 100  [198] 
   Correct classification 88.9  75.9 – 96.3  [59] 
   Incorrect classification 11.1  3.7 – 24.1 Beta [59] 
  Indeterminate results  7  0 –10 Beta [198] 
 Pancreas      
  Classification of tumor specimen 93  90 – 100  [198] 
   Correct classification 85.7  67.3 – 96  [59] 
   Incorrect classification 14.3  4 – 32.7 Beta [59] 
  Indeterminate results  7  0 – 10 Beta [198] 
 Prostate      
  Classification of tumor specimen 93  90 – 100  [198] 
   Correct classification 96  79.6 – 99.9  [59] 
   Incorrect classification  4  0.1 – 20.4 Beta [59] 
  Indeterminate results  7  0 –10 Beta [198] 
 Sarcoma      
  Classification of tumor specimen 93  90 – 100  [198] 
   Correct classification  88.9  70.8 – 97.6  [59] 
   Incorrect classification  11.1  2.4 – 29.2 Beta [59] 
  Indeterminate results  7  0 –10 Beta [198] 
 Thyroid      
  Classification of tumor specimen 93  90 – 100  [198] 
   Correct classification 90.3  74.2 – 98  [59] 
   Incorrect classification 9.7   2 – 25.8 Beta [59] 
  Indeterminate results  7  0 –10 Beta [198] 
 Others       
  Classification of tumor specimen 67    [198] 
   Correct classification  0    [59] 
   Incorrect classification 100    [59] 
  Indeterminate results  33  0–50 Beta [198] 
Distribution of patients across diagnostic results after CRA 
within each occult primary tumor site (%)      
 
Correct classification      
 
 Correct diagnosis of primary  100  90  – 100 Beta [198] 
 
 Undiagnosed primary  0  0  – 10  [198] 
 
Incorrect classification      
 
 Undiagnosed primary  100  90  – 100 Beta [198] 
 
 Incorrect diagnosis  0  0  – 10  [198] 
†  Beta distribution was used for other probability parameter estimates not included in this table. 
PSA= probabilistic sensitivity analysis; MCR= Manitoba Cancer Registry; CUP= Cancer of unknown primary; CRA= Clinicopathologic and 
radiologic assessment.  
85 
 
5.3.4 Costs 
The cost of the TOO test, after all Canadian health system expenses are added, is 
estimated at $4,400 CAD per patient. The management costs of metastatic cancer 
including treatment costs (e.g., surgical procedures, radiation therapy, chemotherapy, 
endocrine therapy, biological therapy, etc.), costs of follow up, costs of managing 
treatment side effects, and cost of palliative care are all publicly funded in Manitoba and 
recorded in the administrative databases held by Manitoba Health. 
I used the Hospital Discharge Database to estimate the costs of inpatients and one day 
procedure stays for our study cohort during their disease course following the initial 
diagnosis. I used the Resource Intensity Weights [201-202] recorded for inpatient stays 
and Day Procedure Group Weights [201-202] recorded for day procedure stays to reflect 
the resources consumed during hospital contacts. I converted these weights into dollars 
using a multiplier known as the Cost Per Weighted Case [201-202]. I used the Physician 
Claims Database to estimate the cost of medical claims made by physicians (and other 
health care providers) for insured services provided to our patient cohort during their 
disease course following the initial diagnosis. In addition, I used the Drug Program 
Information Network to estimate the cost of prescription claims made by our study cohort 
during their disease course following the initial diagnosis. 
I used the costs of hospital stays, medical claims and prescription claims for our study 
cohort to estimate the cost per unit time in each Markov state (Table 10). I used the costs 
collected for metastatic patients diagnosed initially with CUP (i.e., patient group “1”) to 
estimate the cost per unit time in each state of Markov model following the chance nodes 
when the primary stays undiagnosed in both the CCP and TOO-based strategy. I used the 
costs collected for metastatic patients diagnosed initially with their true primary site (i.e., 
patient group “2” stratified by primary tumor site) to estimate the cost per unit time in 
each state of TOO Markov models following the chance nodes when the primary is 
correctly diagnosed. To account for costs associated with incorrect primary diagnosis in 
the TOO-based strategy, I used the costs collected for metastatic patients diagnosed 
initially with their incorrect primary site (i.e., patient group “3” stratified by primary 
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tumor site) to estimate the cost per unit time in each “IDM” state of TOO Markov models 
following the chance nodes when the primary is incorrectly diagnosed. I estimated cost 
per unit time in other states of TOO Markov models following the chance nodes when the 
primary is incorrectly diagnosed by using costs collected for metastatic patients 
diagnosed initially with CUP (i.e., patient group “1” stratified by primary tumor site). All 
costs are expressed in 2013 CAD. 
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Table 10. Base case cost estimates and sources. 
 
Variables  
Base 
case 
value 
Duration 
Distribution 
used in PSA† Data Source 
Cost associated with IDM (per month), $     
 Breast     
  First year after IDM     
   Costs of inpatients and one day procedure stays 983 12 months Normal HA 
   Physicians and other health care providers cost 257 12 months Normal PC 
   Cost of prescription claims 73 12 months Normal DPIN 
  After first year of IDM     
   Costs of inpatients and one day procedure stays 490 Lifetime Normal HA 
   Physicians and other health care providers cost 131 Lifetime Normal PC 
   Cost of prescription claims 89 Lifetime Normal DPIN 
 Colorectal     
  First year after IDM     
   Costs of inpatients and one day procedure stays 1273 12 months Normal HA 
   Physicians and other health care providers cost 533 12 months Normal PC 
   Cost of prescription claims 73 12 months Normal DPIN 
  After first year of IDM     
   Costs of inpatients and one day procedure stays 730 Lifetime Normal HA 
   Physicians and other health care providers cost 284 Lifetime Normal PC 
   Cost of prescription claims 89 Lifetime Normal DPIN 
 Gastric     
  First year after IDM     
   Costs of inpatients and one day procedure stays 1425 12 months Normal HA 
   Physicians and other health care providers cost 398 12 months Normal PC 
   Cost of prescription claims 46 12 months Normal DPIN 
  After first year of IDM     
   Costs of inpatients and one day procedure stays 1372 Lifetime Normal HA 
   Physicians and other health care providers cost 271 Lifetime Normal PC 
   Cost of prescription claims 72 Lifetime Normal DPIN 
 Hepatocellular     
  First year after IDM     
   Costs of inpatients and one day procedure stays 943 12 months Normal HA 
   Physicians and other health care providers cost 185 12 months Normal PC 
   Cost of prescription claims 42 12 months Normal DPIN 
  After first year of IDM     
   Costs of inpatients and one day procedure stays 737 Lifetime Normal HA 
   Physicians and other health care providers cost 19 Lifetime Normal PC 
   Cost of prescription claims 27 Lifetime Normal DPIN 
 Kidney     
  First year after IDM     
   Costs of inpatients and one day procedure stays 1353 12 months Normal HA 
   Physicians and other health care providers cost 373 12 months Normal PC 
   Cost of prescription claims 78 12 months Normal DPIN 
  After first year of IDM     
   Costs of inpatients and one day procedure stays 1019 Lifetime Normal HA 
   Physicians and other health care providers cost 224 Lifetime Normal PC 
   Cost of prescription claims 93 Lifetime Normal DPIN 
 Melanoma     
  First year after IDM     
   Costs of inpatients and one day procedure stays 508 12 months Normal HA 
   Physicians and other health care providers cost 290 12 months Normal PC 
   Cost of prescription claims 78 12 months Normal DPIN 
  After first year of IDM     
   Costs of inpatients and one day procedure stays 748 Lifetime Normal HA 
   Physicians and other health care providers cost 164 Lifetime Normal PC 
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   Cost of prescription claims 85 Lifetime Normal DPIN 
 Non-Hodgkin’s lymphoma     
  First year after IDM     
   Costs of inpatients and one day procedure stays 1620 12 months Normal HA 
   Physicians and other health care providers cost 346 12 months Normal PC 
   Cost of prescription claims 123 12 months Normal DPIN 
  After first year of IDM     
   Costs of inpatients and one day procedure stays 1414 Lifetime Normal HA 
   Physicians and other health care providers cost 183 Lifetime Normal PC 
   Cost of prescription claims 77 Lifetime Normal DPIN 
 Non-small lung      
  First year after IDM     
   Costs of inpatients and one day procedure stays 885 12 months Normal HA 
   Physicians and other health care providers cost 241 12 months Normal PC 
   Cost of prescription claims 33 12 months Normal DPIN 
  After first year of IDM     
   Costs of inpatients and one day procedure stays 773 Lifetime Normal HA 
   Physicians and other health care providers cost 164 Lifetime Normal PC 
   Cost of prescription claims 83 Lifetime Normal DPIN 
 Ovarian     
  First year after IDM     
   Costs of inpatients and one day procedure stays 2618 12 months Normal HA 
   Physicians and other health care providers cost 392 12 months Normal PC 
   Cost of prescription claims 69 12 months Normal DPIN 
  After first year of IDM     
   Costs of inpatients and one day procedure stays 1144 Lifetime Normal HA 
   Physicians and other health care providers cost 187 Lifetime Normal PC 
   Cost of prescription claims 58 Lifetime Normal DPIN 
 Pancreas     
  First year after IDM     
   Costs of inpatients and one day procedure stays 1164 12 months Normal HA 
   Physicians and other health care providers cost 294 12 months Normal PC 
   Cost of prescription claims 36 12 months Normal DPIN 
  After first year of IDM     
   Costs of inpatients and one day procedure stays 1345 Lifetime Normal HA 
   Physicians and other health care providers cost 241 Lifetime Normal PC 
   Cost of prescription claims 171 Lifetime Normal DPIN 
 Prostate     
  First year after IDM     
   Costs of inpatients and one day procedure stays 961 12 months Normal HA 
   Physicians and other health care providers cost 243 12 months Normal PC 
   Cost of prescription claims 60 12 months Normal DPIN 
  After first year of IDM     
   Costs of inpatients and one day procedure stays 771 Lifetime Normal HA 
   Physicians and other health care providers cost 119 Lifetime Normal PC 
   Cost of prescription claims 64 Lifetime Normal DPIN 
 Sarcoma     
  First year after IDM     
   Costs of inpatients and one day procedure stays 1451 12 months Normal HA 
   Physicians and other health care providers cost 552 12 months Normal PC 
   Cost of prescription claims 127 12 months Normal DPIN 
  After first year of IDM     
   Costs of inpatients and one day procedure stays 470 Lifetime Normal HA 
   Physicians and other health care providers cost 119 Lifetime Normal PC 
   Cost of prescription claims 176 Lifetime Normal DPIN 
 Germ cell     
  First year after IDM     
   Costs of inpatients and one day procedure stays 1109 12 months Normal HA 
   Physicians and other health care providers cost 606 12 months Normal PC 
   Cost of prescription claims 129 12 months Normal DPIN 
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  After first year of IDM     
   Costs of inpatients and one day procedure stays 903 Lifetime Normal HA 
   Physicians and other health care providers cost 139 Lifetime Normal PC 
   Cost of prescription claims 26 Lifetime Normal DPIN 
 Thyroid     
  First year after IDM     
   Costs of inpatients and one day procedure stays 854 12 months Normal HA 
   Physicians and other health care providers cost 417 12 months Normal PC 
   Cost of prescription claims 39 12 months Normal DPIN 
  After first year of IDM     
   Costs of inpatients and one day procedure stays 484 Lifetime Normal HA 
   Physicians and other health care providers cost 89 Lifetime Normal PC 
   Cost of prescription claims 45 Lifetime Normal DPIN 
 CUP     
  First year after IDM     
   Costs of inpatients and one day procedure stays 1145 12 months Normal HA 
   Physicians and other health care providers cost 210 12 months Normal PC 
   Cost of prescription claims 51 12 months Normal DPIN 
  After first year of IDM     
   Costs of inpatients and one day procedure stays 541 Lifetime Normal HA 
   Physicians and other health care providers cost 90 Lifetime Normal PC 
   Cost of prescription claims 100 Lifetime Normal DPIN 
Cost associated with latent primary (per month), $     
 Patients initially diagnosed with CUP     
  First year after latent primary     
   Costs of inpatients and one day procedure stays 970 12 months Normal HA 
   Physicians and other health care providers cost 191 12 months Normal PC 
   Cost of prescription claims 88 12 months Normal DPIN 
  After first year of latent primary     
   Costs of inpatients and one day procedure stays 1724 Lifetime Normal HA 
   Physicians and other health care providers cost 150 Lifetime Normal PC 
   Cost of prescription claims 88 Lifetime Normal DPIN 
Cost associated with palliative care (per month), $     
 Breast     
  Costs of inpatients and one day procedure stays 1214 Lifetime Normal HA 
  Physicians and other health care providers cost 236 Lifetime Normal PC 
  Cost of prescription claims 98 Lifetime Normal DPIN 
 Colorectal     
  Costs of inpatients and one day procedure stays 1226 Lifetime Normal HA 
  Physicians and other health care providers cost 204 Lifetime Normal PC 
  Cost of prescription claims 77 Lifetime Normal DPIN 
 Gastric     
  Costs of inpatients and one day procedure stays 790 Lifetime Normal HA 
  Physicians and other health care providers cost 149 Lifetime Normal PC 
  Cost of prescription claims 56 Lifetime Normal DPIN 
 Germ cell     
  Costs of inpatients and one day procedure stays 594 Lifetime Normal HA 
  Physicians and other health care providers cost 10 Lifetime Normal PC 
  Cost of prescription claims 0 Lifetime Normal DPIN 
 Kidney     
  Costs of inpatients and one day procedure stays 1277 Lifetime Normal HA 
  Physicians and other health care providers cost 259 Lifetime Normal PC 
  Cost of prescription claims 184 Lifetime Normal DPIN 
 Hepatocellular     
  Costs of inpatients and one day procedure stays 544 Lifetime Normal HA 
  Physicians and other health care providers cost 142 Lifetime Normal PC 
  Cost of prescription claims 27 Lifetime Normal DPIN 
 Non-small lung     
  Costs of inpatients and one day procedure stays 1116 Lifetime Normal HA 
  Physicians and other health care providers cost 175 Lifetime Normal PC 
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  Cost of prescription claims 67 Lifetime Normal DPIN 
 Non-Hodgkin’s lymphoma     
  Costs of inpatients and one day procedure stays 1012 Lifetime Normal HA 
  Physicians and other health care providers cost 242 Lifetime Normal PC 
  Cost of prescription claims 268 Lifetime Normal DPIN 
 Melanoma     
  Costs of inpatients and one day procedure stays 853 Lifetime Normal HA 
  Physicians and other health care providers cost 241 Lifetime Normal PC 
  Cost of prescription claims 94 Lifetime Normal DPIN 
 Ovarian     
  Costs of inpatients and one day procedure stays 1182 Lifetime Normal HA 
  Physicians and other health care providers cost 158 Lifetime Normal PC 
  Cost of prescription claims 71 Lifetime Normal DPIN 
 Pancreas     
  Costs of inpatients and one day procedure stays 819 Lifetime Normal HA 
  Physicians and other health care providers cost 144 Lifetime Normal PC 
  Cost of prescription claims 55 Lifetime Normal DPIN 
 Prostate     
  Costs of inpatients and one day procedure stays 1358 Lifetime Normal HA 
  Physicians and other health care providers cost 200 Lifetime Normal PC 
  Cost of prescription claims 88 Lifetime Normal DPIN 
 Sarcoma     
  Costs of inpatients and one day procedure stays 1215 Lifetime Normal HA 
  Physicians and other health care providers cost 197 Lifetime Normal PC 
  Cost of prescription claims 112 Lifetime Normal DPIN 
 Thyroid     
  Costs of inpatients and one day procedure stays 463 Lifetime Normal HA 
  Physicians and other health care providers cost 102 Lifetime Normal PC 
  Cost of prescription claims 49 Lifetime Normal DPIN 
 CUP     
  Costs of inpatients and one day procedure stays 1233 Lifetime Normal HA 
  Physicians and other health care providers cost 184 Lifetime Normal PC 
  Cost of prescription claims 83 Lifetime Normal DPIN 
Cost associated with second primary (per month), $     
 Breast     
  Costs of inpatients and one day procedure stays 527 Lifetime Normal HA 
  Physicians and other health care providers cost 265 Lifetime Normal PC 
  Cost of prescription claims 42 Lifetime Normal DPIN 
 Colerectal     
  Costs of inpatients and one day procedure stays 1283 Lifetime Normal HA 
  Physicians and other health care providers cost 511 Lifetime Normal PC 
  Cost of prescription claims 128 Lifetime Normal DPIN 
 Gastric     
  Costs of inpatients and one day procedure stays 464 Lifetime Normal HA 
  Physicians and other health care providers cost 102 Lifetime Normal PC 
  Cost of prescription claims 11 Lifetime Normal DPIN 
 Germ cell     
  Costs of inpatients and one day procedure stays 711 Lifetime Normal HA 
  Physicians and other health care providers cost 1217 Lifetime Normal PC 
  Cost of prescription claims 27 Lifetime Normal DPIN 
 Kidney     
  Costs of inpatients and one day procedure stays 2518 Lifetime Normal HA 
  Physicians and other health care providers cost 285 Lifetime Normal PC 
  Cost of prescription claims 164 Lifetime Normal DPIN 
 Non-small lung     
  Costs of inpatients and one day procedure stays 1147 Lifetime Normal HA 
  Physicians and other health care providers cost 317 Lifetime Normal PC 
  Cost of prescription claims 62 Lifetime Normal DPIN 
 Non-Hodgkin’s lymphoma     
  Costs of inpatients and one day procedure stays 876 Lifetime Normal HA 
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  Physicians and other health care providers cost 343 Lifetime Normal PC 
  Cost of prescription claims 138 Lifetime Normal DPIN 
 Melanoma     
  Costs of inpatients and one day procedure stays 1022 Lifetime Normal HA 
  Physicians and other health care providers cost 437 Lifetime Normal PC 
  Cost of prescription claims 166 Lifetime Normal DPIN 
 Ovarian     
  Costs of inpatients and one day procedure stays 600 Lifetime Normal HA 
  Physicians and other health care providers cost 202 Lifetime Normal PC 
  Cost of prescription claims 29 Lifetime Normal DPIN 
 Prostate     
  Costs of inpatients and one day procedure stays 1573 Lifetime Normal HA 
  Physicians and other health care providers cost 254 Lifetime Normal PC 
  Cost of prescription claims 83 Lifetime Normal DPIN 
 Sarcoma     
  Costs of inpatients and one day procedure stays 1246 Lifetime Normal HA 
  Physicians and other health care providers cost 517 Lifetime Normal PC 
  Cost of prescription claims 256 Lifetime Normal DPIN 
 Thyroid     
  Costs of inpatients and one day procedure stays 219 Lifetime Normal HA 
  Physicians and other health care providers cost 142 Lifetime Normal PC 
  Cost of prescription claims 48 Lifetime Normal DPIN 
 CUP     
  Costs of inpatients and one day procedure stays 910 Lifetime Normal HA 
  Physicians and other health care providers cost 307 Lifetime Normal PC 
  Cost of prescription claims 34 Lifetime Normal DPIN 
Patients initially diagnosed with metastatic hepatocellular and pancreatic cancer did not have a second primary over the study 
follow up period and thus costs associated with second primary are not included for hepatocellular and pancreas.  
PSA= probabilistic sensitivity analysis; MCR= Manitoba Cancer Registry: PC= physician claims; HA= Hospital abstracts; DPIN= 
Drug Program Information Network records; CUP= Cancer of unknown primary; IDM= Initial diagnosis of metastasis. 
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5.3.5 Utilities 
I undertook a systematic review of both primary research studies and economic models to 
determine utilities for each health state in the Markov models (Table 11). I derived 
different utility estimates for metastatic patients diagnosed initially with different known 
primary sites. I assumed that CUP patients whose primary is correctly diagnosed may 
have quality of life outcomes similar to those of metastatic patients diagnosed initially 
with known primary site. 
One recent study has focused on health related quality of life (HRQoL) among CUP 
patients [203]. CUP patients were found to experience 13% more impaired HRQoL 
compared with metastatic patients of known primary. In this study, I estimated the 
weighted average utility of metastatic patients of known primary (i.e., weighted average 
was based on the observed distribution of latent primary tumor sites in our CUP cohort 
(Table 1)) at 0.64 (Table 11). When primary tumor site stays undiagnosed I estimated the 
baseline utility at 0.56 after applying 13% reduction on the weighted average utility of 
metastatic patients of known primary. When patients have the latent primary tumor site 
subsequently detected during their life, I assumed that patients would experience quality 
of life similar to those of metastatic patients diagnosed initially with corresponding 
known primary site. I performed sensitivity analysis on the utility values to account for 
uncertainty. 
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Table 11. Utility values and sources. 
Health states  Utilityβ Duration 
Range tested 
in sensitivity 
analyses 
Distribution 
used in PSA 
Data 
Source 
Initial diagnosis of metastasis      
 Breast 0.715 LT -20% – +20% Beta [60] 
 Colorectal 0.730 LT -20% – +20% Beta [204] 
 Gastric 0.729 LT -20% – +20% Beta [205] 
 Hepatocellular 0.650 LT -20% – +20% Beta [206] 
 Kidney 0.760 LT -20% – +20% Beta [207] 
 Melanoma 0.580 LT -20% – +20% Beta [208] 
 Non-Hodgkin’s lymphoma 0.805 LT -20% – +20% Beta [209] 
 Non-small Lung 0.530 LT -20% – +20% Beta [210] 
 Ovarian 0.740 LT -20% – +20% Beta [211] 
 Pancreas 0.600 LT -20% – +20% Beta [212] 
 Prostate  0.740 LT -20% – +20% Beta [213] 
 Sarcoma  0.690 LT -20% – +20% Beta [214] 
 Testicular germ cell  0.776 LT -20% – +20% Beta [215-216] 
 Thyroid  0.780  LT -20% – +20% Beta [216-217] 
 Other primary tumor sites       
  Buccal cavity and pharynx 0.670    [218] 
  Esophagus 0.670    [218] 
  Small intestine 0.730    [204] 
  Gallbladder 0.650    [206] 
  Non-hepatocellular 0.650    [206] 
  Other digestive system 0.730    [204] 
  Other female genital system 0.740    [211] 
  Other male genital system  0.740    [213] 
  Small cell lung 0.530    [210] 
  Other lung 0.530    [210] 
  Ureter 0.760    [207] 
  Other urinary system  0.760    [207] 
  Multiple myeloma 0.805    [209] 
 
 Other endocrine  0.800    [216-217] 
 Weighted average utility of other 
primary tumor sites^ 0.649 LT -20% – +20% Beta  
 Weighted average utility of metastatic 
patients of known primary^ 0.645 LT -20% – +20% Beta  
 CUP* 0.560 LT -20% – +20% Beta [203] 
Diagnosis of latent primary       
 Patient diagnosed with a given latent 
primary 
Corresponding utility of  
patient initially diagnosed 
with metastasis of that 
primary tumor 
LT -20% – +20% Beta  
Second primary tumor 
7% reduction of 
corresponding utility of a 
given primary tumor site 
LT -20% – +20% Beta [219] 
Palliative care  0.4 LT -20% – +20% Beta [220] 
Death 0     
β All utility estimates were based on EuroQOL five dimensions questionnaire (EQ-5D).  
^ Weighted average was based on the observed distribution of latent primary tumor sites in our CUP cohort.  
* Utility with CUP was derived after applying 13% reduction on the weighted average utility of latent primary tumor sites in CUP.  
CUP= cancer of unknown primary; LT= lifetime.   
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5.4 Results 
5.4.1 Base-case scenario 
There were 1,214 metastatic patients initially diagnosed in Manitoba from January 1, 
2002 to December 31, 2011 with CUP and 405 (33%) of those patients had their latent 
primary tumor site subsequently detected during their life or at autopsy. During the same 
time period, there were 11,731 patients initially diagnosed with metastatic of known 
primary in Manitoba and 2417 (20%) of those patients had their initial primary tumor 
incorrectly identified and their true latent primary tumor detected later during life or at 
autopsy. Patient, tumor, treatment and event characteristics of the study cohort are 
summarized elsewhere [221]. 
Our model predicted 1.13 LY, 0.63 QALY and $17,802 CAD for CUP whereas when 
primary tumor is properly identified our model outcomes ranged from 0.74 LY, 0.45 
QALY, and $14,278 with hepatocellular to 4.35 LY, 3.37 QALY, $69,400 CAD with 
testicular germ cell. A detailed summary for all Markov model outcomes is depicted in 
Table 4. The TOO-based strategy led to an increase of 0.28 LY and 0.24 QALY per 
person and an increase in cost of $10,807 CAD per person, resulting in an incremental 
cost effectiveness ratio (ICER) of $37,774 per LY gained and $44,151per QALY gained 
compared to CCP. Baseline outcomes are summarized in Table 12. 
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Table 12. Baseline Markov model outcomes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary Tumor site  Effectiveness Cost LY QALY  
Breast 1.79 1.08  $30,874 
Colorectal 2.00 1.40  $38,978 
Gastric 1.09  0.73  $26,985 
Hepatocellular  0.74   0.45  $14,278 
Kidney 1.51  1.02  $34,157 
Melanoma 2.30  1.29  $33,056 
Non-Hodgkin’s lymphoma 3.05  2.41  $68,662 
Non-small Lung 1.08  0.53  $20,165 
Ovarian 1.86  1.31  $50,000 
Pancreas 0.75  0.43  $18,157 
Prostate  2.62  1.78  $40,942 
Sarcoma  1.88  1.22  $36,015 
Testicular germ cell  4.35  3.37  $69,400 
Thyroid  3.77  2.97 $40,200 
Unknown primary 1.13  0.63  $17,802 
LY= life year; QALY= quality adjusted life year. 
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Table 13. Baseline study outcomes†. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strategy 
Effectiveness Incremental Effectiveness Cost 
Incremental 
Cost ICER 
LY QALY LY QALY   Per LY gained 
Per 
QALY 
gained  
CCP 1.13 0.63 0.28 0.24 $17,802 $10,807 $37,774 $44,151 TOO test 1.42 0.87 $28,609 
† Due to rounding, numbers may not balance 
CCP= current clinical practice; TOO test= Tissue of Origin test; ICER= incremental cost effectiveness ratio; LY= life 
year; QALY= quality adjusted life year.  
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5.4.2 Sensitivity Analysis 
In three-way sensitivity analysis I tested three groups of parameters: (1) Parameters 
related to sensitivity of the TOO test across occult primary sites (i.e., correct or incorrect 
classification of tumor specimen); (2) Parameters related to incorrect diagnostic results 
following TOO specimen classification (i.e., when primary stays undiagnosed following 
correct TOO classification of tumor specimen or when primary is incorrectly diagnosed 
following incorrect TOO classification of tumor specimen); (3) Parameters related to 
survival response following correct primary diagnosis (i.e., the transition probabilities 
from IDM to PC, SP, or dead states in the TOO Markov models following the chance 
nodes when the primary is correctly diagnosed). The TOO-based strategy generated an 
ICER greater than $100,000 per QALY gained when the sensitivity of the TOO test 
decreased by 50%, incorrect diagnostic results following TOO specimen classification 
increased by 20% and survival response following correct primary diagnosis decreased 
by 30% (Figure 6). Cost of the test and indeterminate TOO results across occult primary 
sites did not substantially influence our baseline outcomes (Figure 7). 
I performed a probabilistic sensitivity analysis (Figure 8a) comparing the TOO versus 
CCP-based strategy. I simultaneously varied all parameters (probabilities, utilities and 
costs) using appropriate distributions (Table 1, 2 and 3). Using a willingness to pay 
threshold of $50,000 and $100,000 per QALY gained, I found that the TOO-based 
strategy was the preferred strategy in 78.2% and 99.6% of simulations respectively 
(Figure 8b). 
I also performed a value-of-information analysis [112] to determine the expected 
monetary value of perfect information about the impact of TOO test. This analysis is 
necessary to estimate the societal impact of future research that can evaluate the TOO test 
in real life Canadian clinical practice [112]. In particular, I set up our baseline model to 
express all parameters related to the accuracy of the TOO test, diagnostic results 
following TOO specimen classification, and survival response following correct primary 
diagnosis as probability distributions (Table 9) and the entire model is set up as a 
probabilistic model. I assessed the level of uncertainty in the model using simulation 
techniques (i.e., making 1000 random draws of the probabilistic model). Using our 
baseline ICER value of $44,151 per QALY gained as our willingness to pay, the 
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opportunity cost associated with the choice of TOO-based strategy for guiding 
management of CUP resulted in a total of expected value of perfect information (EVPI) 
of $1,265.81 per patient diagnosed with CUP. Subsequently, I estimated the expected 
value for the entire CUP population that could potentially benefit from more research on 
the predictive value of the TOO test and its impact in the Canadian setting. In Manitoba, 
there were 105 patients diagnosed with CUP in 2011. Based on the size of Manitoba 
relative to the rest of Canada, I anticipate a total of approximately 2,923 patients annually 
diagnosed with CUP who would be eligible for the TOO test in Canada. The resulting 
population EVPI was 3.7million per year. 
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Figure 6. Sensitivity of the ICER to TOO accuracy1, incorrect diagnostic 
results2following TOO classification and survival response3following correct primary 
diagnosis. 
a b 
Baseline Survival Response Following Correct Primary 
Diagnosis 
10% Decrease of Baseline Survival Response Following 
Correct Primary Diagnosis 
 
 
c d 
20% Decrease of Baseline Survival Response Following 
Correct Primary Diagnosis 
30% Decrease of Baseline Survival Response Following 
Correct Primary Diagnosis 
  
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Pe
rc
en
ta
ge
 
In
cr
ea
se
 
o
f I
n
co
rr
ec
t D
ia
gn
o
st
ic
 
re
su
lts
 
fo
llo
w
in
g 
TO
O
 
C
la
ss
ifi
ca
tio
n
 
 
 
 
 
 
 
Percentage Decrease of Baseline TOO 
Accuracy
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Pe
rc
en
ta
ge
 
In
cr
ea
se
 
o
f I
n
co
rr
ec
t D
ia
gn
o
st
ic
 
re
su
lts
 
fo
llo
w
in
g 
TO
O
 
C
la
ss
ifi
ca
tio
n
 
 
 
 
 
 
 
Percentage Decrease of Baseline TOO 
Accuracy
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Pe
rc
en
ta
ge
 
In
cr
ea
se
 
o
f I
n
co
rr
ec
t D
ia
gn
o
st
ic
 
re
su
lts
 
fo
llo
w
in
g 
TO
O
 
C
la
ss
ifi
ca
tio
n
 
 
 
 
 
 
 
Percentage Decrease of Baseline TOO 
Accuracy
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Pe
rc
en
ta
ge
 
In
cr
ea
se
 
o
f I
n
co
rr
ec
t D
ia
gn
o
st
ic
 
re
su
lts
 
fo
llo
w
in
g 
TO
O
 
C
la
ss
ifi
ca
tio
n
 
 
 
 
 
 
 
Percentage Decrease of Baseline TOO 
Accuracy
100 
 
     ICER ≤ $50,000 per QALY gained                                                                                    $50,000 < ICER ≤ $100,000 per QALY 
     $100,000 < ICER ≤ $150,000 per QALY                                                                           ICER > $150,000 per QALY 
1TOO test agreement with reference cancer diagnosis. 
2Incorrect diagnostic result was defined as when primary stays undiagnosed following correct TOO classification of tumor 
specimen or when primary is incorrectly diagnosed following incorrect TOO classification of tumor specimen. 
3
 Survival response following correct primary diagnosis was defined as the transition probabilities from IDM to PC, SP, or dead 
states in the TOO Markov models following the chance nodes when the primary is correctly diagnosed. Survival response 
following correct diagnosis of hepatocellular, pancreas or non-small lung primary site was not included in sensitivity analyses as 
these potential primary sites were found to have worse QALYs compared to overall CUP group (Table 4). 
TOO test= Tissue of Origin test; ICER= incremental cost effectiveness ratio; QALY= quality adjusted life year; CUP= cancer of 
unknown primary. 
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Figure 7. Sensitivity of the ICER to cost of the TOO test and indeterminate TOO results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TOO test= Tissue of Origin test; ICER= incremental cost effectiveness ratio; QALY= quality adjusted life 
year. 
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Figure 8. Incremental cost-effectiveness scatter plot and acceptability curve of TOO 
versus CCP-based strategy. Sampling distributions and summary estimates of cost, 
efficacy, and variance were based on 1000 replicates. 
a 
Incremental Cost Effectiveness Scatter plot of TOO versus CCP-based Strategy  
 
b 
Cost-Effectiveness Acceptability Curve of TOO versus CCP-based Strategy 
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TOO test= Tissue of Origin test; CCP= current clinical practice. 
0
5
10
15
20
25
0 0.1 0.2 0.3 0.4 0.5
In
cr
em
en
ta
l c
o
st
 
(th
o
u
sa
n
ds
 
o
f d
o
lla
rs
)
Incremental  effectiveness (QALY)
0%
20%
40%
60%
80%
100%
15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100
Pr
o
ba
bi
lit
y 
o
f b
ei
n
g 
co
st
 
ef
fe
ct
iv
e
Willingness to pay ($/QALY) gained'000s
104 
 
5.5 Discussion 
I developed a decision-analytic model to evaluate the cost effectiveness of using the TOO 
test to help diagnose primary tumors versus CCP in patients with CUP for whom no 
anatomical primary tumor site was found after diagnostic work up undertaken according 
to real life clinical practice in Manitoba. In the base case I found that the TOO-based 
strategy has an ICER of $37,774 per LY gained and $44,151 per QALY gained. 
In Canada, an ICER of $20,000 to $100,000 per QALY gained has been suggested as 
representing “moderate evidence for adoption and appropriate utilization” [62, 72], 
although there is no evidence that any Canadian decision-making body has formally 
implemented these thresholds [168]. The ICER of the TOO-based strategy in patients 
with CUP were within ranges of the microarray-based 21-gene expression test for breast 
cancer that has recently been partly adopted in clinical practice in Canada [124-126]. The 
21-gene assay for guiding adjuvant chemotherapy in early stage breast cancer has an 
estimated ICER of up to $63,064 per QALY gained [132]. It became available in several 
provinces in a limited fashion or within context of a field evaluation for hormone positive 
and lymph node negative disease [124-126]. 
A recent cost-effectiveness analysis of the TOO test was reported among patients with 
metastatic and poorly differentiated cancer of uncertain primaries (i.e. difficult-to-
diagnose primary) for whom the majority had primary tumor site diagnoses reported by 
their physicians prior to TOO testing. The test was found to have an ICER of $46,858 per 
QALY gained from a US third-party payer perspective. These results in uncertain cancers 
cannot be extrapolated to the CUP setting since with CUP, despite extensive clinical and 
pathological diagnostic evaluation, patients are left without a primary tumor site 
diagnosis and as a result management and clinical outcomes are different. In our study I 
examined the cost-effectiveness of incorporating TOO testing in patients diagnosed with 
CUP for who all had no anatomically defined primary tumor site after the diagnostic 
work up that was undertaken according to real life clinical practice in Manitoba. 
Our sensitivity analysis (Figure 6a) demonstrated that the accuracy of the TOO test in 
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classifying tumor specimens and diagnostic results following TOO tumor classification 
are important drivers of the ICER. Both factors further impacted the ICER when 
addingthe possibility that CUP patients may not respond as well as their counterparts 
with metastatic of known primary cancers when occult primary is identified and treated 
with current site-specific therapy (i.e. survival response following correct primary 
diagnosis). For instance, when these three factors were negatively modified by 
approximately 35% (Figure 6d) the ICER became well above ranges of a number of 
cancer treatments recently approved for funding in Canada [169-170] and TOO-based 
strategy may no longer deemed a cost effective use of resources. 
Validation of the TOO test accuracy and clinical verification of resulting diagnostic 
decisions in real-life CUP population remains a challenge since, by definition, the 
primary tumor site is not found except rarely in the clinical course or commonly at 
autopsy [10, 222]. Analyses of the TOO tests [59, 198] used in our study were conducted 
in the United States in patients with known primary cancers. Genetic profiles of occult 
cancers giving rise to CUP may differ from known primary cancers [222]. A more direct 
study to evaluate the reliability of TOO test and its impact on diagnostic decision making 
in CUP patients would be the correlation with an eventual primary tumor detected later 
during the course of the disease (latent primary) or at autopsy. Such research approach 
would be useful in the Canadian setting to address concerns over potential incorrect TOO 
classification and resulting diagnostic decisions and to update our model and verify our 
results. 
Our value of information analysis demonstrated that future research that can characterize 
the TOO test accuracy and resulting diagnoses and survival outcomes in CUP-real world 
Canadian practice may have a large societal impact, when willingness to pay levels of 
recently accepted cancer treatments are considered. Taken together with the lack of future 
randomized trials of TOO testing in CUP population worldwide, this suggests that field 
evaluations of the test to establish its impact on Canadian management of CUP and 
resulting survival outcomes should be a priority. 
Controversies have recently been raised on whether validation analyses of gene 
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expression profiling assays may have been subject to tumor-biopsy specimen sampling 
bias due to potential intratumoral heterogeneity [223]. Although analysts have run the 
TOO test on duplicate samples from 44 cases (both clinical and research cases) and found 
no differences in test outcome, I still remain uncertain as to whether these concordant 
results may apply on the overall heterogeneous CUP population.  Thus, future studies of 
TOO testing in CUP population should further explore any potential impact of 
intratumoral heterogeneity on its results using multiple tumor-biopsy samples. 
Our analysis has limitations. First, there are limits to what can be ascertained through 
administrative data. Even though the Manitoba Cancer Registry is a highly accurate 
source of information about all cancer sites [137], errors in coding can result in incorrect 
or unrecorded procedures. However, wherever possible I cross validated across 
databases. For instance, information on palliative care can be found in both the Manitoba 
Cancer Registry and the administrative databases held by Manitoba Health. Second, 
outcomes and costs of therapies given in the 2002-2011 population do not necessary 
reflect the possible benefits and costs of newer types of therapies or dosing schedules 
used in current practice so analysis with such data would be more applicable to the 
current practice landscape. Finally, although clinical practice patterns employed in the 
selected time period in Manitoba have shown to reflect practices in other jurisdictions in 
Canada [88, 174-175], management of patients with CUP and its associated costs could 
be different. 
5.6 Conclusion 
I compared the use of TOO test to aide in primary tumor diagnosis versus CCP in patients 
diagnosed with CUP.  I found that the TOO-based strategy appears to provide good value 
for money in this patient population. However, field evaluations of the test to establish its 
accuracy and impact on diagnostic decisions and survival in the CUP setting should be 
initiated in Canada to ensure its clinical utility and cost-effectiveness. 
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Chapter 6  
6 General discussion 
6.1 Implications and recommendations 
Creating evidence-based review of gene expression profiling technologies in clinical 
oncology is becoming the primary challenge with the limited evidence base available 
[224]. In particular, randomized controlled clinical trials and other high-quality evidence 
is generally lacking for these technologies [225]. Moreover, Canadian data on patient and 
clinician behavior based on these gene expression profiling results and the outcomes of 
treatment decisions (i.e., effectiveness) may not be available [224]. I used Manitoba 
administrative health databases and Manitoba Cancer Registry to parameterize decision 
analytic models and predict the role of such emerging gene expression profiling 
technologies in real world Canadian clinical oncology practice. This approach may have 
increased model complexity but it has the advantage of providing us with longitudinal 
patient, clinical and treatment data on a large number of patients and for a long follow up 
time. This allowed us to estimate significant clinical outcomes (e.g. local recurrence, 
regional recurrence, second primary, chemotherapy-related serious adverse effects, and 
latent primary) that are otherwise hard to model using secondary data sources. This thesis 
highlights the usefulness of the Canadian provincial administrative health databases and 
disease registries as a source of information to inform health care decision making and 
policy development. In Canada, administrative health and disease registry data have been 
used for research purposes for decades. It was the establishment of the Manitoba Center 
for Health Policy and Evaluation and the subsequent development of their population 
health information system, POPULIS, which brought this data source into the spotlight. 
Similar developments in other Canadian provinces since that time now offer health 
researchers access to provincial administrative health data that can be linked across 
services [82]. A more thorough discussion of the use of registry and administrative data 
to conduct cost-effectiveness analyses in the Canadian setting has been discussed 
elsewhere [188]. 
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It should be noted that emerging gene expression profiling technologies may not yet be 
incorporated into the Canadian clinical practice and thus data about these technologies 
may not be available from provincial administrative health databases or disease registries 
in Canada. However, I have shown that analysts can still predict the role of these 
technologies in real-world clinical practice when these databases are used to model 
current real-world Canadian clinical practices (the current practice without these 
technologies). Analysts can then apply available data about these technologies, which 
might be derived from non-Canadian settings, on observed current clinical practice 
models to examine how these data may alter the observed current clinical and economic 
outcomes. Such decision modeling and cost-effectiveness analyses are helpful in 
identifying data needs and quantifying uncertainty about these technologies in the real 
world Canadian setting. For instance, value of information analysis (VOI) [112] can be 
performed on these decision analytic models to inform policy options such as 
conditionally funded field evaluation (CFFE) (i.e., coverage with evidence development) 
[113]. 
Canadian provincial decision makers (e.g., the Ontario Health Technology Advisory 
Committee (OHTAC)) are currently facing promising gene expression profiling  (e.g., 
21-gene assay) that may improve patient safety and likely pose low risk of harm, but have 
significant uncertainty associated with their clinical value [87, 226]. In such cases, 
Canadian decision makers can recommend promising gene expression profiling 
technologies for a conditionally funded field evaluations (CFFE) to be undertaken to 
reduce uncertainty, and this could take the form of studies on quality, safety, efficacy, 
effectiveness, and cost-effectiveness [113]. For instance, following a recommendation by 
OHTAC, in Ontario the 21-gene assay became available for women with early stage 
lymph node negative breast cancer within the context of field evaluation in December 
2010 [227]. Organizations that provide the analysis to support provincial decision making 
bodies (e.g. The Programs for Assessment of Technology in Health (PATH) Research 
Institute) often use VOI analyses to determine the expected value of perfect information 
(EVPI) about the technology. Comparing the EVPI with the cost of conducting a CFFE 
can determine if it is worthwhile before actually conducting the evaluation [113]. If the 
CFFE is determined not to be worthwhile (i.e., the cost of research is greater than the 
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VOI gained from the research), this information is fed back to high level decision makers 
and CFFE would not be considered [113]. On the other hand, if it is determined that the 
CFFE is worthwhile, information on uncertainty from the economic model is further used 
to refine CFFE study design. Hence, our VOI analyses in this thesis are likely relevant to 
Canadian provincial decision makers who must make difficult decisions. 
A close observation on the pharmaceutical industry may demonstrate that Canadian 
decision makers will increasingly face this scenario with gene expression profiling and 
other personalized medicine technologies in the near future and therefore use of health 
administrative health data in decision analytic analyses should be a priority. The use of 
administrative databases to model existing clinical practices would be the best approach 
that analysts can take to predict the role of these technologies when compared with 
existing clinical practices in real-world settings and to support health technology 
assessment. 
In addition, a current paradigm shift in pharmaceutical industry strongly suggests the 
need to build an evidence base for clinical practice and policies in Canada using 
provincial administrative health databases and disease registries. In this era, it becomes 
reasonable to forgo randomized phase III clinical trials for drugs and medical 
technologies that demonstrate substantial activity in early-phase clinical trials, 
particularly for diseases with high unmet medical need [228]. In Canada, pharmaceutical 
companies can get accelerated drug approval from the Therapeutic Product Directorate 
(TPD) of Health Canada through the Notice of Compliance (NOC) policy which requires 
less onerous evidentiary requirements and the review process itself is also significantly 
accelerated [229].  In turn this will allow promising new drugs and technologies to 
potentially be made widely available to patients sooner by avoiding the delays and cost 
that seem inherent in completing phase III randomized clinical trials [228-230]. However, 
forgoing randomized phase III clinical trials leads to less-definitive data regarding the 
safety and efficacy of the new drug or technology [228]. Thus, conducting post-
marketing studies to confirm clinical benefit becomes necessary. The Health Products 
and Food Branch (HPFB) in Canada has, by virtue of the Food & Drugs Act and 
regulations, nominal jurisdiction to ensure a manufacturer’s compliance through post-
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market surveillance [229]. When this occurs, drugs and medical technologies might be 
released into the marketplace and their availability might deter patient participation in 
post-marketing studies. Many pharmaceutical companies have failed or faced difficulties 
in completing randomized or non-randomized confirmatory post-marketing studies due to 
poor patient accrual [228, 231]. Decision analytic modeling techniques might then be 
used to assess indirect evidence. In this regard, provincial health administrative databases 
and disease registries in Canada may provide a great opportunity to assess the clinical 
effectiveness of such drugs in real world Canadian clinical practice. It should be noted 
that the development of specific billing codes for new drugs and emerging medical 
technologies should be a priority in this era [232]. Such an effort will allow provincial 
health administrative databases and disease registries to capture the use of these drugs or 
technologies in the Canadian clinical practice [233]. In addition, analysts will be able to 
conduct their decision modeling and cost-effectiveness analyses to assess effectiveness 
and inform recommendations for appropriate clinical decision making. Such an effort will 
contribute to building a high quality evidence base for examining these drugs and 
technologies in real-world Canadian clinical practice. As well, efforts to maintain and 
develop health administrative data standards across provinces, specifically to monitor 
new drugs and emerging technologies through coding development would be helpful for 
cross-regional comparisons. Provincial and territorial health ministries and disease 
registries which hold and maintain administrative and registry data should share and 
allow use of these data to academics and pharmaceutical industry. For instance, allowing 
pharmaceutical companies to access Canadian health administrative databases and 
disease registries will be helpful in conducting confirmatory post-marketing studies on 
their drugs or medical technologies which might be a unique and effective tool for these 
companies to assess the clinical and cost effectiveness of their products in real-world 
settings [228, 230-231]. 
Given the promising role of health administrative data in this era, the process of 
accessing and linking provincial health administrative databases and registries in Canada 
should be accelerated and improved across all Canadian provinces. At the same time, it is 
essential to ensure there is adequate privacy and security protection for personal health 
information when data sets are linked. For instance, in Ontario, a collaborative agreement 
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between the Institute for Clinical Evaluative Sciences (ICES) and Cancer Care Ontario 
(CCO) has lead to the initiation of the Ontario Cancer Data Linkage Project (‘cd-link’). 
This was an initiative of the Ontario Institute for Cancer Research and Cancer Care 
Ontario Health Services Research Program to establish a data release program whereby 
administrative datasets relevant to cancer health services research such as the Ontario 
Cancer Registry and Ontario Health Insurance Plan claims are linked, de-identified and, 
with the protections of a comprehensive Data Use Agreement, provided directly to 
researchers. Such a provincial initiative is helping to speed research that contributes to 
the effectiveness, quality, equity and efficiency of health care and health services 
in Ontario. Similar initiatives in other Canadian provinces should be developed to offer 
health researchers and other stakeholders’ access to provincial health administrative and 
registry data that can be efficiently linked across services. 
 Currently, the emphasis in virtually all analyses evaluating gene expression profiling 
technologies in clinical oncology is on the establishment of the value of each of these 
profiling predictors over standard clinical predictors. However, as gene expression 
profiling technologies mature and proliferate, an important question will be how they 
compare to each other when these technologies target the same patient population, and 
whether there is value in their combination or sequencing. In the therapeutic domain, this 
has been called “comparative effectiveness” research. Such research has traditionally 
been difficult to fund by government or by industry, because it may not hold out as much 
therapeutic promise as new discoveries and industry understandably is not anxious to 
fund head-to-head comparisons with competitive products. In the diagnostic domain, 
such research is necessary to compare the effectiveness of combining different available 
diagnostic technologies. For instance, Gould et al. developed a decision analytic model to 
identify the most effective approaches to diagnose and manage solitary pulmonary 
nodules [234]. Gould et al. compared 40 clinically plausible combinations of 5 available 
diagnostic interventions, including computed tomography, positron emission tomography 
with the glucose analogue 18-fluorodeoxyglucose (FDG-PET), transthoracic needle 
biopsy, surgery, and watchful waiting [234]. This same dynamic could easily take hold in 
the gene expression profiling arena with a proliferation of licensed gene expression 
assays without any clear notion of what new ones are contributing over previous assays. 
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Thus, future decision analyses of new gene expression profiling technologies in clinical 
oncology should study their incremental clinical and economic value over pre-existing 
gene expression profiling and clinicopathologic methods. For instance, our breast cancer 
decision analytic model can be expanded to project the lifetime clinical and economic 
consequences of early stage breast cancer under many different treatment strategies. Such 
a model may begin with a decision to use the MammaPrint, the RS-assay, the RS-assay 
following by the MammaPrint, Adjuvant!Online (AOL) following by the RS-assay, AOL 
following by the MammaPrint or to continue with CCP.  
6.2 Conclusion 
The potential applications of certain gene expression profiling assays in clinical oncology 
appear to be clinically promising and economically attractive in the Canadian healthcare 
system. However, uncertainty about these gene expression profiling assays in real world 
Canadian setting remains the primary challenge for adoption. Novel funding models such 
as conditional funding alongside a field evaluation of these assays to establish their 
impact on cancer management and patient survival may have a large societal impact and 
should be initiated in Canada to ensure their clinical utility and cost-effectiveness. 
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